A database of RNA aptamers
Example: RNA aptamer SELEX ATP-aptamer Structure
Detailed information
This section displays| Name | Target | Sequence | Length | GC Content | Affinity | Year |
|---|---|---|---|---|---|---|
| CB3GA_Szostak_1 | Cibacron Blue 3GA | 5'GGGAGAAUUCCCGCGGCAGAAGCCCACCUGGCUUUGAACUCUAUGUUAUUGGGUGGGGGAAACUUAAGAAAACUACCACCCUUCAACAUUACCGCCCUUCAGCCUGCCAGCGCCCUGCAGCCCGGGAAGCUU3' | 132 | 56.06% | Kd~600µM | 1990 |
| RB4_Szostak_1 | Reactive Blue 4 | 5'GGGAGAAUUCCCGCGGCGUUGGCCCAGGAUAAUAGGACGAAAUCCGAAAAAUCCGUACCCAACAUAGAACCCCCCCAGCGCUCACACGGACGCCCCAUUACGGCUAACCGAACGCCUGCAGCCCGGGAAGCUU3' | 133 | 59.40% | Kd<100µM | 1990 |
| T4 DNA pol_Gold_1 | T4 DNA polymerase (gp43) | 5'GAAUUGUGGUGUUGGCUCCCUAUAGUGAGUCGUAUUAAUAUUCCUUAGUUUUAUAGCCCAAUAACUCAGGCUCUUGAUUGGUUUUCAAUAGAGAUAUAAAAUUCUUUUCAUAG3' | 113 | 33.63% | Kd: 4.8 nM | 1990 |
| T4 DNA pol_Gold_2 | T4 DNA polymerase (gp43) | 5'GAAUUGUGGUGUUGGCUCCCUAUAGUGAGUCGUAUUAAUAUUCCUUAGUUUUAUAGCCCAGCAACCUAGGCUCUUGAUUGGUUUUCAAUAGAGAUAUAAAAUUCUUUUCAUAG3' | 113 | 35.40% | Kd: 4.8 nM | 1990 |
| HIV-1-RT_Gold_1 | Human imunnodeficiency virus type 1 reverse transcriptase (HIV-1-RT) | 5'GGGAGCAUCAGACUUUUAAUCUGACAAUCAAGAAUUCCGUUUUCAGUCGGGAAAAACUGAACAAUCUAUGAAAGAAUUUUAUAUCUCUAUUGAAAC3' | 96 | 33.33% | Kd: 5 nM | 1992 |
| HIV-1-RT_Gold_2 | Human imunnodeficiency virus type 1 reverse transcriptase (HIV-1-RT) | 5'GGGAGCAUCAGACUUUUAAUCUGACAAUCAAGAAUAUCUUCCGAAGCCGAACGGGAAAACCGGCAUCUAUGAAAGAAUUUUAUCUCUAUUGAAAC3' | 95 | 38.95% | Kd: 5 nM | 1992 |
| bFGF_Janjić_1 | Basic fibroblast growth factor (bFGF) | 5'GGGAGCUCAGAAUAAACGCUCAAAUCUCCUCCCGUCGAAGCUAACCUGGCCACUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 58.44% | Kd: 23 ± 3 nM | 1993 |
| bFGF_Janjić_2 | Basic fibroblast growth factor (bFGF) | 5'GGGAGCUCAGAAUAAACGCUCAAUCGGCGAGCUAACCAAGACACUCGCUGCACUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 58.44% | Kd: 5.0 ± 0.5 nM | 1993 |
| bFGF_Janjić_3 | Basic fibroblast growth factor (bFGF) | 5'GGGAGCUCAGAAUAAACGCUCAAACCCGCGGCCUCCGAAGCUAACCAGGACACUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 61.04% | Kd: 3.2 ± 0.5 nM | 1993 |
| bFGF_Janjić_4 | Basic fibroblast growth factor (bFGF) | 5'GGGAGCUCAGAAUAAACGCUCAAUGGGUGCUAACCAGGACACACCCACGCUGUUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 58.44% | Kd: 3.0 ± 0.5 nM | 1993 |
| bFGF_Janjić_5 | Basic fibroblast growth factor (bFGF) | 5'GGGAGCUCAGAAUAAACGCUCAAUGGGUGCUUAACCAGGCCACACCCUGCUGUUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 58.44% | Kd: 8.1 ± 0.8 nM | 1993 |
| bFGF_Janjić_6 | Basic fibroblast growth factor (bFGF) | 5'GGGAGAUGCCUGUCGAGCAUGCUGGGGGCAACGCUACAGACAAGUGCACCCAACGUAGCUAAACAGCUUUGUCGACGGG3' | 79 | 58.23% | Kd: exhibits biphasic binding, 0.51 ± 0.13 nM, 60 ± 52 nM | 1993 |
| bFGF_Janjić_7 | Basic fibroblast growth factor (bFGF) | 5'GGUGAAGGCAACGUAUAGGCAAGCACACUUCACC3' | 34 | 52.94% | Kd: ~0.19 ± 0.02 nM | 1993 |
| bFGF_Janjić_8 | Basic fibroblast growth factor (bFGF) | 5'GGGAGAUGCCUGUCGAGCAUGCUGCGUCAGAAGGCAACGUAUAGGCAAGCACACGUAGCUAAACAGCUUUGUCGACGGG3' | 79 | 55.70% | Kd: exhibits biphasic binding, 0.19 ± 0.02 nM, 49 ± 26 nM | 1993 |
| bFGF_Janjić_9 | Basic fibroblast growth factor (bFGF) | 5'GGGAGAUGCCUGUCGAGCAUGCUGAGGGUAACGUACUGGCAAGCUCACCUCAGCGUAGCUAAACAGCUUUGUCGACGGG3' | 79 | 56.96% | Kd: exhibits biphasic binding, 0.13 ± 0.03 nM, 510 ± 30 nM | 1993 |
| bFGF_Janjić_10 | Basic fibroblast growth factor (bFGF) | 5'GGGAGAUGCCUGUCGAGCAUGCUGAGGGUAACGUAUAGUCAAGACACCUCAAGUGUAGCUAAACAGCUUUGUCGACGGG3' | 79 | 51.90% | Kd: exhibits biphasic binding, 0.32 ± 0.07 nM, 140 ± 80 nM | 1993 |
| Rev-binding element_Ellington_1 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGGCGCAGCCUCAAUGAGGCUGGUGGUGCAAG3' | 38 | 63.16% | Kd: 1.9 ± 0.21* | 1993 |
| Rev-binding element_Ellington_2 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGGCGCAGCCUCAAUGAGGCUGGAGGUACAAG3' | 38 | 60.53% | Kd: 2.0* | 1993 |
| Rev-binding element_Ellington_3 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGGCACAGCCUCAAUGAGGCUGGUGGUACAAG3' | 38 | 57.89% | Kd: 1.2 ± 0.08* | 1993 |
| Rev-binding element_Ellington_4 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGACACAGCCUCAAUGAGGCUGCAGAUACAAG3' | 38 | 52.63% | Kd: 3.1 ± 0.26* | 1993 |
| Rev-binding element_Ellington_5 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGACACAGCUGCUGCAGAUACAAG3' | 30 | 53.33% | Kd: 2.1* | 1993 |
| Rev-binding element_Ellington_6 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGACACAGCCUCAAUGAGGCUGCAGAAACAAG3' | 38 | 52.63% | Kd: 2.7 ± 0.29* | 1993 |
| Rev-binding element_Ellington_7 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'GCUCUUGGCCGCAGCCUCAAUGAGGCUGAUGAUACAAG3' | 38 | 55.26% | Kd: 1.7* | 1993 |
| Rev-binding element_Ellington_8 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUACUCCGUACGCAAGUACGGUCGAGAAACAG3' | 37 | 48.65% | Kd: 4.3* | 1993 |
| Rev-binding element_Ellington_9 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUUUAGGACUCGUACGCAAGUACUGAGAUACUACAG3' | 41 | 41.46% | Kd: 2.4* | 1993 |
| Rev-binding element_Ellington_10 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUCCUGGCUCGUACGCAAGUACUAGAGACACAG3' | 38 | 50.00% | Kd: 3.6* | 1993 |
| Rev-binding element_Ellington_11 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACUCGUACGCAAGUACUGGAGAAACAG3' | 34 | 47.06% | Kd: 5.4 ± 0.05* | 1993 |
| Rev-binding element_Ellington_12 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGGACUCGUACGCAAGUACUUGAGAUACACG3' | 37 | 45.95% | Kd: 3.1* | 1993 |
| Rev-binding element_Ellington_13 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGUCUCGUACGCAAGUACUGAGAAACGACAG3' | 36 | 47.22% | Kd: 0.4* | 1993 |
| Rev-binding element_Ellington_14 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACUCCGUAUGCAAGUACGUUGAGCAACAG3' | 36 | 47.22% | Kd: 7.7, 9.5, 9.6* | 1993 |
| Rev-binding element_Ellington_15 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUAGACUCGUACGCAAGUACUCGAGAUAUACAG3' | 38 | 42.11% | Kd: 4.2* | 1993 |
| Rev-binding element_Ellington_16 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUUGGACUCCGUACGCAAGUACGUCGAGAUACAG3' | 39 | 48.72% | Kd: 1.9* | 1993 |
| Rev-binding element_Ellington_17 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGGACUCGUACGCAAGUACUGAGAAACACCG3' | 37 | 48.65% | Kd: 3.6* | 1993 |
| Rev-binding element_Ellington_18 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGACUCUUUGUACGCAAGUACAGAGUGAUACAG3' | 39 | 41.03% | Kd: 1.4* | 1993 |
| Rev-binding element_Ellington_19 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACGCGUACGCAAGUACUGUGAUACAG3' | 33 | 48.48% | Kd: 4.1* | 1993 |
| Rev-binding element_Ellington_20 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACGCGCUGGUACGCAAGUACGGCUGUGAUACAG3' | 40 | 55.00% | Kd: 3.9* | 1993 |
| Rev-binding element_Ellington_21 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUAGGUUGAGGUACGCAGACGGCUCUCUACAG3' | 37 | 51.35% | Kd: 1.9* | 1993 |
| Rev-binding element_Ellington_22 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUACUCUCGUACGCAAGUACGAUCGAGACACAG3' | 38 | 47.37% | Kd: 2.6* | 1993 |
| Rev-binding element_Ellington_23 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGAGCUCGUACGCAAGUACUCGAGGUACAG3' | 36 | 50.00% | Kd: 1.0* | 1993 |
| Rev-binding element_Ellington_24 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUUUGGAGGUACGCAAGUACGCGCUCACAG3' | 35 | 51.43% | Kd: 2.0* | 1993 |
| Rev-binding element_Ellington_25 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUACUCCUGUACGCAAGUACGGUUGAGACACAG3' | 38 | 47.37% | Kd: 3.2* | 1993 |
| Rev-binding element_Ellington_26 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUAUGAGAGUAGCAAGUACCGGACUCUACAG3' | 36 | 44.44% | Kd: 0.3* | 1993 |
| Rev-binding element_Ellington_27 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGCUCGUGUACGCAAGUACGCUUGAGGAACAG3' | 38 | 50.00% | Kd: 1.4* | 1993 |
| Rev-binding element_Ellington_28 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGUAGAGGUACGCAAGUACGCGCUCCACAG3' | 36 | 52.78% | Kd: 6.4, 6.5, 7.4, 9.7* | 1993 |
| Rev-binding element_Ellington_29 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUUUUUGAGGUACGCAAGUACGCGGCUCGACAG3' | 38 | 50.00% | Kd: 2.3* | 1993 |
| Rev-binding element_Ellington_30 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGUGUAGAGGUACGCAAGUAAGCGGCUCCACAG3' | 37 | 51.35% | Kd: 7.4* | 1993 |
| Rev-binding element_Ellington_31 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGUACGUUGUACGCAAGUACACGGGUUACAG3' | 36 | 47.22% | Kd: 0.7* | 1993 |
| Rev-binding element_Ellington_32 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGCUUCGUACGCAAGUAUGAUGAUACAG3' | 33 | 42.42% | Kd: 0.2* | 1993 |
| Rev-binding element_Ellington_33 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACAUCGUACGCAAGUACCUUGAAACAG3' | 34 | 44.12% | Kd: 4.6* | 1993 |
| Rev-binding element_Ellington_34 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACUUCGGUACGCAAUUACCGACUGACACAG3' | 37 | 48.65% | Kd: 2.4* | 1993 |
| Rev-binding element_Ellington_35 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCUGGACAUUUGUACGCAAGUACGUUUGAUACAG3' | 36 | 38.89% | Kd: 3.9* | 1993 |
| Rev-binding element_Ellington_36 | Rev protein of HIV-1 (minimal Rev-binding element (RBE) found within the Rev Responsive Element (RRE)) | 5'AUUCGGUAGCAUCUUGUACGCAAGUACGAGAGAGCAACAG3' | 40 | 47.50% | Kd: 0.5* | 1993 |
| Thrombin_Tasset_1 | α-Thrombin, Human | 5'GGGAGAUGCCUGUCGAGCAUGCUGCAUCCGGAUCGAAGUUAGUAGGCGGAGUGGUAGCUAAACAGCUUUGUCGACGGG3' | 78 | 56.41% | Kd: 37 ± 3.5 nM | 1994 |
| Thrombin_Tasset_2 | α-Thrombin, Human | 5'GGGAGAUGCCUGUCGAGCAUGCUGGUGCGGCUUUGGGCGCCGUGCUUGACGUAGCUAAACAGCUUUGUCGACGGG3' | 75 | 61.33% | Kd: 114 ± 2.0 nM | 1994 |
| Thrombin_Tasset_3 | α-Thrombin, Human | 5'UCCGGAUCGAAGUUAGUAGGCGGA3' | 24 | 54.17% | Kd: 9.3 ± 1.0 nM | 1994 |
| Thrombin_Tasset_4 | α-Thrombin, Human | 5'GAGCAUGCUGGUGCGGCUUUGGGCGCCGUGCUU3' | 33 | 66.67% | Kd: 155 ± 9.0 nM | 1994 |
| VB12_Szostak_1 | Cyanocobalamin (vitamin B12) | 5'GUCGGCCUAUCCGACAGGCACCGCGAGAGGACCAUUAUAGUGCGCAUAACCACUUCAGUGCGAGCAAAAAUUUGG3' | 75 | 53.33% | Kd: 88 ± 19 nM | 1994 |
| Co(III)(CN)6_Szostak_1 | Cobinamide dicyanide | 5'GUCGGCCUAUCCGACAGGCACCGCGAGAGGACCAUUAUAGUGCGCAUAACCACUUCAGUGCGAGCAAAAAUUUGG3' | 75 | 53.33% | Kd: 20 ± 9 μM | 1994 |
| Co(III)(CN)6_Szostak_2 | Cobinamide dicyanide | 5'AACACUAUCCGACUGGCACCGCCAGCGGACAAAUCCGGUGCGCAUAACCACCUCAGUGCGAGCAACGAUGGCCUUUCUACCCAAAGAUUUUCCUUGGUCAUUAGGAUCC3' | 109 | 53.21% | Kd: 8.8 ± 0.5 μM | 1994 |
| VB12_Szostak_2 | Cyanocobalamin (vitamin B12) | 5'AACACUAUCCGACUGGCACCGCCAGCGGACAAAUCCGGUGCGCAUAACCACCUCAGUGCGAGCAACGAUGGCCUUUCUACCCAAAGAUUUUCCUUGGUCAUUAGGAUCC3' | 109 | 53.21% | Kd: 320 ± 90 nM | 1994 |
| VB12_Szostak_3 | Cyanocobalamin (vitamin B12) | 5'GGAACCGGUGCGCAUAACCACCUCAGUGCGAGCAA3' | 35 | 60.00% | Kd: 88 ± 19 nM | 1994 |
| Co(III)(CN)6_Szostak_3 | Cobinamide dicyanide | 5'GGAACCGGUGCGCAUAACCACCUCAGUGCGAGCAA3' | 35 | 60.00% | Kd: 19.7 ± 8.7 μM | 1994 |
| Theophylline_Polisky_1 | Bronchodilator theophylline | 5'AGUGAUACCAGCAUCGUCUUGAUGCCCUUGGCAGCACU3' | 38 | 52.63% | Kd: 0.1 μM | 1994 |
| Theophylline_Polisky_2 | Bronchodilator theophylline | 5'AAGUGAUACCAGCAUCGUCUUGAUGCCCUUGGCAGCACUUCA3' | 42 | 50.00% | Kd: 0.6 μM | 1994 |
| Citrulline_Tocchini-Valentini_1 | L-citrulline [L-(+)-2-amino-5-ureidovaleric acid] | 5'GACGAGAAGGAGUGCUGGUUAUACUAGCGGUUAGGUCACUCGUC3' | 44 | 52.27% | Kd: 62-68 µM | 1994 |
| Arginine_Tocchini-Valentini_1 | L-arginine | 5'GACGAGAAGGAGCGCUGGUUCUACUAGCAGGUAGGUCACUCGUC3' | 44 | 56.82% | Kd: 56-76 µM | 1994 |
| PKC βII_Newton_1 | Protein kinase C beta II (protein kinase C βII) | 5'GGGAGAAUUCCGACCAGAGGCUUACAGAGUGUGCGUAAUGGCGUUCCCAAAUUCGGGCUGGGAACCGUUCGUUCGUGUUAUGCCCGUAGAUAUGGCAAGUCGCGGAUGCUCAGUACUACACUCUUGUGGUCAGUCACAUAUGUGCGUCUACAUGGAUCCUCA3' | 162 | 51.85% | Kd: 7 nM | 1994 |
| PKC βII_Newton_2 | Protein kinase C beta II (protein kinase C βII) | 5'GGGAGAAUUCCGACCAGAGGUUGUUAAGUGCGAGUUGUUUUACUCCGAUGAUACGGGGAGCGUUAGAGUCUUAUGACCUUGUUCUCCACGUCACUGUCCAAGUCACUCCGCGUCAUAGCAGUCGGAUCCUGUACAUAUGUGCGUCUACAUGGAUCCUCA3' | 159 | 49.69% | Kd: 7 nM | 1994 |
| VEGF_Janjić_1 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAACCGGUAGUCGCAUGGCCCAUCGCGCCCGGUUCGACAUGAGGCCCGGAUCCGGC3' | 76 | 64.47% | Kd1: 0.20 ± 0.02 nM Kd2: 42 ± 30 nM | 1994 |
| VEGF_Janjić_2 | Vascular Endothelial Growth Factor (VEGF) | 5'GGCCGGUAGUCGCAUGGCCCAUCGCGCCCGG3' | 31 | 77.42% | Kd1: 0.42 ± 0.04 nM Kd2: 182 ±94 nM | 1994 |
| VEGF_Janjić_3 | Vascular Endothelial Growth Factor (VEGF) | 5'GGAAGCUUGAUGGGUGACACACGUCAUGCCGAGCU3' | 35 | 57.14% | Kd1: 0.48 ± 0.04 nM Kd2: 82 ± 23 nM | 1994 |
| VEGF_Janjić_4 | Vascular Endothelial Growth Factor (VEGF) | 5'GGAAGGGAACCUGCGUCUCGGCACCUUCG3' | 29 | 65.52% | Kd1: 1.1 ±0.2 nM Kd2: 180 ± 160 nM | 1994 |
| VEGF_Janjić_5 | Vascular Endothelial Growth Factor (VEGF) | 5'GGUCAACGGUUGAGUCUGUCCCGUUCGAC3' | 29 | 58.62% | Kd1: 20 ± 1 nM | 1994 |
| VEGF_Janjić_6 | Vascular Endothelial Growth Factor (VEGF) | 5'GGCUCAAUAGUUGGAGGCCUGUCCUCGCCGUAGAGC3' | 36 | 61.11% | Kd1:1.8 ±0.4 nM Kd2: 31 ± 10 nM | 1994 |
| VEGF_Janjić_7 | Vascular Endothelial Growth Factor (VEGF) | 5'GGAACGGUUCUGUGUGUGGACUAGCCGCGGCCGUU3' | 35 | 62.86% | Kd1: 1.4 ±0.2 nM Kd2: 181 ± 57 nM | 1994 |
| VEGF_Janjić_8 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAAAGCUUGAUGGGUGACACACGUCAUGCCGAGCUUUUCGACAUGAGGCCCGGAUCCGGC3' | 80 | 56.25% | Kd1: 1.7 ±0.5 nM Kd2: 38 ±32 nM | 1994 |
| VEGF_Janjić_9 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAAGCAGACGAAGGGAACCUGCGUCUCGGCACCUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 61.04% | Kd1: 0.48 ± 0.07 nM Kd2: 21 ±5 nM | 1994 |
| VEGF_Janjić_10 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAAGCUUGAUGGGUGACACACGUCAUGCCGAGCUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 58.44% | Kd1: 0.19 ±0.09 nM Kd2: 10 ± 1 nM | 1994 |
| VEGF_Janjić_11 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAAGCUCAAUAGUUGGAGGCCUGUCCUCGCCGUAGAGCGUUCGACAUGAGGCCCGGAUCCGGC3' | 83 | 59.04% | Kd1: 0.82 ±0.2 nM Kd2: 21 ± 5 nM | 1994 |
| VEGF_Janjić_12 | Vascular Endothelial Growth Factor (VEGF) | 5'GGGAGCUCAGAAUAAACGCUCAAAACGGUUCUGUGUGUGGACUAGCCGCGGCCGUUUUCGACAUGAGGCCCGGAUCCGGC3' | 80 | 58.75% | Kd1: 0.14 ±0.04 nM Kd2: 11 ± 3 nM | 1994 |
| HTLV-1_Ellington_1 | Tax protein of the human T-cell lymphomatic virus (HTLV-1) | 5'GGGAGAAUUCCGACCAGAAGCUUGGACUUAUUCUCGAGCCUGCAUGUGCUAGUCGACGUUGUUUCUGCAUCUUGAAAGAUGGGGCUGUGGGUGUGGUUACUUCUACGCGGUAUGCACUGUACGCCCCAUAUGUGCGUCUACAUGGAUCCUCA3' | 152 | 51.32% | Kd: 70 nM | 1995 |
| Tobramycin_Rando_1 | Tobramycin | 5'GGGAGAAUUCCGACCAGAAGCUUCGUUUGGGGUCCCACAACACAGGUCUUUGCUGGUCAUAUAUGCGUGUCCUCUAGGAAGUGCAUAUGUGCGUCUACAUGGAUCCUCA3' | 109 | 50.46% | Kd: 4.3 ± 0.7 µM | 1995 |
| Tobramycin_Rando_2 | Tobramycin | 5'GGGAGAAUUCCGACCAGAAGCUUCUGGUUAGUUUUGCACAGUGGUCGAUGCUAGACUUGGUUUAGGUAAUGAGUCCAAUAGUCCAUAUGUGCGUCUACAUGGAUCCUCA3' | 109 | 45.87% | Kd: 3 ± 1 nM (high affinity component); 15.9 ± 0.7 µM (low affinity component) | 1995 |
| Tobramycin_Rando_3 | Tobramycin | 5'GGGAGAAUUCCGACCAGAAGCUUAGUAUAGCGAGGUUUAGCUACACUCGUGCUGAUCGUUUGGUACGGGACCUGCGUGUAGCCCAUAUGUGCGUCUACAUGGAUCCUCA3' | 109 | 51.38% | Kd: 2 ± 1 nM (high affinity component); 6.0 ± 0.4 µM (low affinity component) | 1995 |
| VPF/VEGF_Janjić_1 | Vascular pemeability factor/vascular endothelial growth factor (VPF/VEGF) | 5'GGGAGACAAGAAUAACGCUCAAACCCUGAUGGUAGACGCCGGGGUGCCGGAAUUCGACAGGAGGCUCACAACAGGC3' | 76 | 57.89% | NA | 1995 |
| HIV-1 integrase_Gold_1 | Human immunodeficiency virus (HIV-1) integrase | 5'GGGAGCUCAGAAUAAACGCUCAACCAGUCUUGUGGCUUUGAAAGAGAGGAGUGUUCGACAUGAGGCCCGGAUCCGGC3' | 77 | 54.55% | Kd: 12 nM or 2 nM | 1995 |
| Lividomycin_Ellington_1 | Aminoglycoside lividomycin | 5'GGGAAUGGAUCCACAUCUACGAAUUCAACGAGUGCAGUGGGAAACAGGUCUUUGGCUUCACUGCAGACUUGACGAAGCUU3' | 80 | 48.75% | NA | 1996 |
| Lividomycin_Ellington_2 | Aminoglycoside lividomycin | 5'GGGAAUGGAUCCACAUCUACGAAUUCCCGUCAAGUCCGGUAAGGUGCCUGACGUCUUCACUGCAGACUUGACGAAGCUU3' | 79 | 51.90% | NA | 1996 |
| Arginine_Famulok_1 | L-arginine | 5'GGAGCUCAGCCUUCACUGCAUGAUAAACCGAUGCUGGGCGAUUCUCCUGAAGUAGGGGAAGAGUUGUCAUGUAUGGGGGCACCACGGUCGGAUCCUG3' | 97 | 55.67% | Kd: 330 nM | 1996 |
| HIV-1 Rev_Ellington_1 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGCUAGGCAAUGUUUCGGUUGGAGUAAUCCGGUGGCUUGCCAUGAUUUACGUGAGUGCUGAUCCGUGAUGAGAUAGUAAGUGCAAUCU3' | 110 | 45.45% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_2 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGCUAGGCAAUGUUUCGGUUGGAGUAAUCCGGUGGCUUGCCAUGAUUUACGUGAGUGCUGAUCCGUGAUGAGAUAGUAAGUGCAAUCU3' | 110 | 45.45% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_3 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGUAUUCUCGGUGGUUUAAUCUGUGUAGAGGAGCUGACUCCUUUGGUUGGACUACGUGGAGGUUCUCUUAGAUAGUAAGUGCAAUCU3' | 109 | 43.12% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_4 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUCAAGAAGUGGAAAUGCGCAGCGACCAUGAAACCUCGCAUGGUUCAUCGAUUGUUUGGAUAGUGUCUGUGUGAGAUAGUAAGUGCAAUCU3' | 112 | 43.75% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_5 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGCAGUUAACCAAGCCUGCAUACUGGAUAGACGGCUUAUCCGACUGAAUGCCUCCCGAAAGGUGCAGUUAGAUAGUAAGUGCAAUCU3' | 109 | 45.87% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_6 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGCGCAAACCCGAAGAAUGCCCAAAUUGAUCCAGAGCAAGUGGGAAUGAUAUAAAGUACCUGGUCCUGGAGAUAGUAAGUGCAAUCU3' | 109 | 44.04% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_7 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUUCCAAACCCCGUUGAGAGUUGAUCCGGUCUAGGGAAUGGGAAAGAAGUAGGUAUCGAAGAGAAUGUACCCUAGAUAGUAAGUGCAAUCU3' | 112 | 43.75% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_8 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUAGGACUCAAAUAUUCACGUUGACGUUGUCUUGGAGUGCUGAUCGGAAAACCAAUAUGAUUAAUGGGUCCUGAGAUAGUAAGUGCAAUCU3' | 112 | 40.18% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_9 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUACGCAGCGACUGUGGUGGUGAGCGGUUGCGUAACUUGAUUUAAGCAAGUACUGCCAUGGCCGAACCUCUAAGAUAGUAAGUGCAAUCU3' | 111 | 46.85% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_10 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUUCUAGUCAAGUUGCAAUCUCCGGUGGGGUGGUAACCGAGGAACACGUUUCGGGUGUAUAGGCUAGCGAGAUAGUAAGUGCAAUCU3' | 108 | 47.22% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_11 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUUCUACCAGAGCGAGUGUGCUGAACGUUCUAAGGACGGGAUUGAAUCGAGAUGCGUAUACUAGGACCUUACGAGAUAGUAAGUGCAAUCU3' | 112 | 44.64% | Kd: 19-36 nM | 1996 |
| HIV-1 Rev_Ellington_12 | Human immunodeficiency virus type 1 Rev (HIV-1 Rev) | 5'GGGAGAUACCAGCUUAUUCAAUUGCUUGGUACCGAGCUCGGAUCCACGUAGUAACGGGCCGCCAGUGUCUGGAAUUCGGGUCGUUCUUGAGAUAGUAAGUGCAAUCU3' | 107 | 50.47% | Kd: 19-36 nM | 1996 |
| LS-Rg_Varki_1 | L-selectin receptor globulin (LS-Rg) | 5'UCGGGCGAGUCGUCUGUAACAACAAUCAAGGCGGGUUCACCGCCCCAGUAUGAGUACCGCAUCGUCCUCCC3' | 71 | 59.15% | Kd: 0.2 nM-3 nM | 1996 |
| LS-Rg_Varki_2 | L-selectin receptor globulin (LS-Rg) | 5'UCGGGCGAGUCGUCUGCGCGUAUGUGUGAAAGCGUGUGCACGGAGGCGUCUACAAUCCGCAUCGUCCUCCC3' | 71 | 61.97% | Kd: 3 nM-4 nM | 1996 |
| D-arginine_Ellington_1 | D-arginine | 5'CGGAUGGAAGGCGUGGUUAGAAUCCAAUAGCCCAUCCG3' | 38 | 55.26% | Kd: 135 ± 25 µM | 1996 |
| Arginine_Ellington_1 | L-arginine | 5'CGGAUGGAAGGCGUGGUUAGAAUCCAAUAGCCCAUCCG3' | 38 | 55.26% | Kd: 129 ± 18 µM | 1996 |
| ATP_Breaker_1 | Adenosine triphosphate (ATP) | 5'GGGCGACCCCAGUGCAUUGCGAAGAAACUGUGCGACUUCGGUCGCAGCAAACGUCGGC3" 5'GCCGUAGGUUGCCC3' | 72 | 63.89% | NA | 1997 |
| ATP_Breaker_2 | Adenosine triphosphate (ATP) | 5'UUUGUAGGCGACCUACCACUCUCGUGGCCCAGUGCAUUGCUGCGACCGAAGUCGCCAGUUUCUUCCCAAAUGUCGUCGCCAUCUCUUCC3' | 89 | 56.18% | NA | 1997 |
| HCV_Nishikawa_1 | NS3 protease of hepatitis C virus (HCV) | 5'GGGAACUCGAUGAAGCGAAUUCUGUUGGCGAACUGUACGCAAGUACACUGGAUGACAGGCCUAUCUAUCGGAUCCACG3' | 78 | 51.28% | Kd: 650 nM | 1997 |
| Dopamine_Tocchini-Valentini_1 | Dopamine | 5'GGGAAUUCCGCGUGUGCGCCGCGGAAGACGUUGGAAGGAUAGAUACCUACAACGGGGAAUAUAGAGGCCAGCACAUAGUGAGGCCCUCCUCCCAGUCCGUUCGGGAUCCUC3' | 111 | 58.56% | Kd: 2.8 µM | 1997 |
| Prion protein_Winnacker_1 | Prion protein rPrP23-231 (rPrPc) fused to glutathione S-transferase (GST), RecombiNAt Syrian golden hamster | 5'GGAGCUCAGCCUUCACUGCACGAAUUCGUUGUGCGGGAAUUUGAGGGACGAUGGGGAAGUGGGACGAAUGACUCAUUGCCGCGGUAGGGUUAGGCACCACGGUCGGAUCC3' | 110 | 58.18% | NA | 1997 |
| Prion protein_Winnacker_2 | Prion protein rPrP23-231 (rPrPc) fused to glutathione S-transferase (GST), RecombiNAt Syrian golden hamster | 5'GGAGCUCAGCCUUCACUGCAGCAAUGCGUUGUGUGGGAAUUUGAGGGACGAUGGGGAAGUGGGGACGAAUGACUCAUUGCCGCGGUAGGGUUGGCACCACGGUCGGAUCC3' | 110 | 59.09% | NA | 1997 |
| Prion protein_Winnacker_3 | Prion protein rPrP23-231 (rPrPc) fused to glutathione S-transferase (GST), RecombiNAt Syrian golden hamster | 5'GGAGCUCAGCCUUCACUGCUACCUUAGAGUAGGAGCGGGACGAGGGGUUGUUGGGACGUGGGUAUGAUCCAUACAUUAGGAAGCUGGUGAGCUGGCACCACGGUCGGAUCC3' | 111 | 57.66% | NA | 1997 |
| Cam_Gold_1 | Chloramphenicol (Cam) | 5'GGGAAAAGCGAAUCAUACACAAGAAUGAAAAGGGCUGGCGAGACAUAUCCGCUGGGCAAUCAGAUUCGGAGCCGCACCACCCUCGAAGUAGACAGGGCAUAAGGUAUUUAAUUCCAUA3' | 118 | 48.31% | Kd: 2.1 ± 0.3 µM | 1997 |
| Cam_Gold_2 | Chloramphenicol (Cam) | 5'GGGAAAAGCGAAUCAUACACAAGAAGAGCUUGACGGUCCCGAGAGUCGAGCCCAAGCUGACACUGGACCUUUGCGGACCACGUGUUGAUCGUCGGGGCAUAAGGUAUUUAAUUCCAUA3' | 118 | 50.85% | Kd: 8 ± 4 µM | 1997 |
| Cam_Gold_3 | Chloramphenicol (Cam) | 5'GGGAAAAGCGAAUCAUACACAAGAGGCACCAAAGCUGAAGUAGCGGGAUAACUCAAAUUACUUUAGGUGUAUGAAGGUGAAACUAGCAAUGAAGGGCAUAAGGUAUUUAAUUCCAUA3' | 117 | 39.32% | Kd: 7 ± 2 µM | 1997 |
| Cam_Gold_4 | Chloramphenicol (Cam) | 5'GGGCAUAAGGUAUUUAAUUCCAUACGGCAGACGAGCCUUGACGAGCCAAUCUACACUUGGCGAUGACCGAUGGGCCCCAGCUACUUCUGGCAGUUUCGAUUCGUUUGAUUCGGAUGCUCGGUAGCUCAACUCG3' | 133 | 51.88% | Kd: 25 ± 3 µM | 1997 |
| B52_Lis_1 | B52 protein | 5'GGGAGAAUUCAACUGCCAUCUAGGCAGGGUAACGAUCAACCUGGCGACAGCUGCCCUGCCGUCCAAGUACUACAAGCUUCUGGACUCGGU3' | 90 | 55.56% | Kd: 50nM | 1997 |
| B52_Lis_2 | B52 protein | 5'GGGAGAAUUCAACUGCCAUCUAGGCUGGUCAACCAGGCGACCGCCACCCGCGCGCGCAAUACCUAGUACUACAAGCUUCUGGACUCGGU3' | 89 | 58.43% | Kd: 20nM | 1997 |
| B52_Lis_3 | B52 protein | 5'GGGAGAAUUCAACUGCCAUCUAGGCUGCUCACGAGUCCAUGACCAGUACGAUCAACCAGGCGACAGUACUACAAGCUUCUGGACUCGGU3' | 89 | 52.81% | NA | 1997 |
| B52_Lis_4 | B52 protein | 5'GGGAGAAUUCAACUGCCAUCUAGGCCCAACUGCUAAGAAGCAUCCUGUACGAUCAACCCGGCGACAGUACUACAAGCUUCUGGACUCGGU3' | 90 | 52.22% | NA | 1997 |
| RNA loop_Schmidt_1 | RNA stem-loop target (5'GCACGGTGCTGCTGAGATGCCCGT3') | 5'GGGAGAAUUCCGACCAGAAGCUUCCGAAGCAUUCCGGCGUAGGGGUCUGUGCGCAAAACCAUCGGCCCUGGUGCCUAUGUGCGUCUACAUGGAUCCUCA3' | 99 | 57.58% | Kd: 70 ± 15 nM | 1997 |
| PNA pol II_Sentenac_1 | RNA polymerase II (Pol II), Saccharomyces cerevisiae (S. cerevisiae) | 5'GGGCCGCUAAGUCCUCGCUCACGAUACAGCACUGAUUGCGGUCGAGGUAGCUUGAUGGGCCACGCGCGACUCGGAUCCAC3' | 80 | 62.50% | NA | 1997 |
| K ras_Rando_1 | Farnesylated peptide modeled after the carboxyl terminus of K ras | 5'GGGAGAAUUCCGACCAGAAGCCUGCUCAGGGGUGGGUCGUAUAAUUAGCGUAGGGAGGUAGUGGAUGAGUAAGCCUGGGAUGUCAUAUGUGCGUCUACAUGGAUCCUCA3' | 109 | 52.29% | Kd: 139 ± 12 nM | 1997 |
| K ras_Rando_2 | Farnesylated peptide modeled after the carboxyl terminus of K ras | 5'GGGAGAAUUCCGACCAGAAGCCUGAGAUGUAUCGUUGCCGGGGAUGGGUGGGUGGUGUGAAGGCGAUCGUCAUCAGUUCGAGCCAUAUGUGCGUCUACAUGGAUCCUCA3' | 109 | 55.05% | Kd: 0.93 ± 0.05 μM | 1997 |
| HCV_Nishikawa_2 | NS3 Protein of Hepatitis C Virus (HCV) | 5'GGGAGAAUUCCGACCAGAAGGCUUGCUGUUGUUUCCCUGUUGUUUUGUCUCUCAACUUUAUUGUGGUAAAGAUCACUGGGUUGAUAAGGGCUAACUCUAAUUUGACUACAUGGUCGGACCAAUCAGUUCUUAUGGGAGAUGCAUAUGUGCGUCUACAUGGAUCCUCA3' | 167 | 43.71% | Kd: 120 ± 18 nM | 1997 |
| HCV_Nishikawa_3 | NS3 Protein of Hepatitis C Virus (HCV) | 5'GGGAGAAUUCCGACCAGAAGCUUAUACUGAAUUAAUCGCUACCGUGUCAUUGUACUUGGUAGUGUUGAUGGUUUGGGUCGCAUUUGGCUUGGCUUAUGGUUUUUUCACCCUACCUCUCAUUGACGCACUAGGCUCUCAUAUGUGCGUCUACAUGGAUCCUCA3' | 162 | 45.68% | NA | 1997 |
| SelB_Famulok_1 | Special elongation factor SelB of Escherichia coli | 5'GUCAGGAUGACUGCUGCGCUCGUGUCGUCACUGACCAUCUGUCGCAGGUCUGCGCACAUCGGUCGUUCACGGCCCAUCGGUUGCAGGUCUGCACCAAUCGGUCGGUAAUGGCGCAAUGAGCAUUACGGAUUCAAGC3' | 136 | 58.09% | binding ratio: 2.0 | 1997 |
| Xanthine_Yokoyama_1 | Xanthine (2,6-dioxypurine) | 5'GGCACGUGUAUUACCCUAGUGGUCGACGUGCC3' | 32 | 59.38% | Kd: 3.3 µM | 1998 |
| Guanine_Yokoyama_1 | Guanine | 5'GGCACGUGUAUUACCCUAGUGGUCGACGUGCC3' | 32 | 59.38% | Kd: 1.3 µM | 1998 |
| APC_Nishikawa_1 | Activated protein C (APC), Human | 5'GGGAGAAUUCCGACCAGAAGCUUGUGAGACCAGCCGAGUGGUGUCUGGCUAUUCACUGGAGCGUGGGUGGAACCCCUGCGCACUCGUUUGGCUGUCCGGGCCUUCGGGCCGGGAUUAUCUCUUUGGGUUUUGUGAUUUGGUCAUAUGUGCGUCUACAUGGAUCCUCA3' | 167 | 55.69% | Ki: 83 ± 17 nM | 1998 |
| APC_Nishikawa_2 | Activated protein C (APC), Human | 5'GUGAGACCAGCCGAGUGGUGUCUGGCUAUUCACUGGAGCGUGGGUGGAACCCCUGCGCACUCGUUUGGCUGUCCGGGCCUUCGGGCCGGGAUUAUCUCU3' | 99 | 62.63% | Ki: 137 ± 14 nM | 1998 |
| Sulforhodamine B_Wilson_1 | Fluorophore sulforhodamine B | 5'GGAACACUAUCCGACUGGCACCUGUGCUCUAUAGCAGAAUGCUAACAUUAGAUGAUGGAGGGGCGCAAGGUUAACCGCCUCAGUACAUCGGUGCCUUGGUCAUUAGGAUCCCG3' | 113 | 52.21% | Kd: 70 ± 10 nM | 1998 |
| Fluorescein_Wilson_1 | Fluorescein | 5'GGACGGCACCACGGUCGGAUCCGUGAGUUGUGACAAUUUAGCGGGUGGUAUUAGAGCCUACUGCCACAGCAAUAGGAUCGAUACAGAUCU3' | 90 | 52.22% | NA | 1998 |
| PTPase_Ellington_1 | Protein tyrosine phosphatases (PTPase) ( Yop51*Δ162 ), Yersinia | 5'GGGAAUGGAUCCACAUCUACGUAUUACUGCUGGUGACGAGGGCUAGACGACGUACCUUCACUGCAGACUUGACGAAGCUU3' | 80 | 51.25% | Kd: 28 ± 12 nM | 1998 |
| PTPase_Ellington_2 | Protein tyrosine phosphatases (PTPase) ( Yop51*Δ162 ), Yersinia | 5'GGGAGAUACCAGCUUAUUCAAUUCUGGCAAUGGGCUAUCCCAAGUGCUAGGCUUCAGGGAGCGAGGACCAGACGACGUACCUAACCCUAAGGUGAGAUAGUAAGUGCAAUCU3' | 112 | 50.00% | Kd: 18 ± 2.9 nM | 1998 |
| Raf-1 RBD_Yokoyama_1 | Glutathione S-transferase-fused RBD (GST-RBD) Ras-binding domain (Raf-1 RBD) | 5'GGGAGAUCAGAAUAAACGCUCAACUGAUCAAUGGCGUACAAUGGAUUCGUUCUCAUAACCAAAACCCUUACCCCUUGGACUGAUUCGACAUGAGGCCCCUGCAGGGCG3' | 108 | 50.00% | Kd: 332 ± 93 nM | 1998 |
| Raf-1 RBD_Yokoyama_2 | Glutathione S-transferase-fused RBD (GST-RBD) Ras-binding domain (Raf-1 RBD) | 5'GGGAGAUCAGAAUAAACGCUCAAUUGACUCAAUGGCGUACAAUGGAUUCGUUCUCAUAACCAAAACCCUUACCCCUUGGACUGUUCGACAUGAGGCCCCUGCAGGGCG3' | 108 | 50.00% | Kd: 332 ± 93 nM | 1998 |
| Tobramycin_Rando_4 | Tobramycin | 5'GGCUUAGUAUAGCGAGGUUUAGCUACACUCGUGCUGAGCC3' | 40 | 52.50% | Kd: 5.15 ± 1.52 nM | 1998 |
| bFGF_Ellington_1 | RecombiNAt basic fibroblast growth factor (bFGF), Human | 5'GGGAAUGGAUCCACAUCUACGAAUUCAAUCCCAAUGGCUUGAACUGCCAACGAACGUUCACUGCAGACUUGACGAAGCUU3' | 80 | 47.50% | Kd: 1.8 ± 0.8 nM | 1998 |
| Streptomycin_Schroeder_1 | Streptomycin | 5'GGAGCUCAGCCUUCACUGCACCCCUUUGUGGGAACGCAAAACUAAAGGAAGAUCUCAAGAAAGGUGGAUCGCAUUUGGACUUCUGCCCAGGGUGGCACCACGGUCGGAUCCAC3' | 113 | 54.87% | NA | 1998 |
| Streptomycin_Schroeder_2 | Streptomycin | 5'GGAUCGCAUUUGGACUUCUGCCCAGGGUGGCACCACGGUCGGAUCC3' | 46 | 63.04% | NA | 1998 |
| Streptomycin_Schroeder_3 | Streptomycin | 5'GGAGCUCAGCCUUCACUGCCAGACAGUAGAGGGAAGUGUGAGCUAUCACCUCAAGGAAAACGCUUCAGAAAGGGACUUAGGUGAUGAUAGUGUGGCACCACGGUCGGAUCCAC3' | 113 | 53.10% | NA | 1998 |
| Streptomycin_Schroeder_4 | Streptomycin | 5'AUCACCUCAAGGAAAACGCUUCAGAAAGGGACUUAGGUGAU3' | 41 | 43.90% | NA | 1998 |
| SelB_Famulok_2 | SelB protein, Escherichia coli | 5'GCGCUAAGUCCUCGCUCAGCCCAUAAGUUGUCCCAAGUCUUGGGCGCAAAUACAUCCCACGCGCGACUCGGAUCCG3' | 76 | 59.21% | NA | 1999 |
| tRNA_Tocchini-Valentini_1 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCUACGUAUCUUCAGGCGGUAACUAACUGUGCUGAGUCUAAUCUUUGUGAGGGACGGUAACAUAUGGUUCCCGCGUGGUCCGUUCGGGAUCCUC3' | 109 | 53.21% | Kd: 12 ± 1.2 nM | 1999 |
| tRNA_Tocchini-Valentini_2 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCAAGCCUGUCGUGUGAACCUUGGUAGUCUUCAGAUACCAUUCUAGCCACGAGAGACUACGACACUGCUCCGUCGCCCGUCCGUUCGGGAUCCUC3' | 110 | 57.27% | Kd: 26 ± 1.4 nM | 1999 |
| tRNA_Tocchini-Valentini_3 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCUCGGUCACGCAUCUUCACGUCGAAAGCUACAUCGGUCUGCUGACGGUGAUGGCAUUUGCGCGGCUUACGCCGGUCGUGGUCCGUUCGGGAUCCUC3' | 112 | 60.71% | binding efficiency:40% | 1999 |
| tRNA_Tocchini-Valentini_4 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCAGAGUGGCCGGGCCUCCAUUCGGGGGUUAUCUUCACCUACGGGCCCCACGCGUUAUUUAGUGUUGUACCGUAGGGCUGUGUCCGUUCGGGAUCCUC3' | 113 | 60.18% | binding efficiency:37% | 1999 |
| tRNA_Tocchini-Valentini_5 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCGGGUCUUCACAGACUUGGCAAUUACCAGAACAUGUGCCUGGUAUACGUCAAUACGUCUGGUGGUUAAUACCGCCGUGGUCCGUUCGGGAUCCUC3' | 111 | 54.05% | binding efficiency:41% | 1999 |
| tRNA_Tocchini-Valentini_6 | Phenylalanine tRNA, Yeast | 5'GGGAAUUCCGCGUGUGCAUCACGGGUGUAUGCAAGACUCAGCAGUGGGCCAUAUGGUCGGAUCGAGGCUAGCUAAGUCUCCCAAUUGCACCUUCGUGGUCCGUUCGGGAUCCUC3' | 114 | 57.02% | binding efficiency:16% | 1999 |
| CD18_Famulok_1 | Cytoplasmic domain of CD18 | 5'GGGCGCUAAGUCCUCGCUCAUGCGCGUCCCAUGGGGUAUAGAGGGGUCGAAGUGGACGCGCGACUCGGAUCCUAC3' | 75 | 64.00% | Kd: between 500 and 1,000 nM | 1999 |
| CD18_Famulok_2 | Cytoplasmic domain of CD18 | 5'GGGCGCUAAGUCCUCGCUCAUACAACGAGGGGUCGUGUAGGGAUGUAUGGGCUUGGACACACGCGCGACUCGGAUCCUAC3' | 80 | 60.00% | Kd: between 500 and 1,000 nM | 1999 |
| CD18_Famulok_3 | Cytoplasmic domain of CD18 | 5'GGGCGCUAAGUCCUCGCUCACAAGGUGCAAUGCAAUAUGUGAGUGCGCCGCCCUUUCUCUCGCGCGACUCGGAUCCUAC3' | 79 | 59.49% | Kd: between 500 and 1,000 nM | 1999 |
| BPN_Kikuchi_1 | Subtilisin BPN | 5'GGGCGAAUUCGAGCUCGGGCCACUCGCUCAACACGGUAAGUAGAGACCUAGUGGUACAUAAAGGACUGCAGGCAUGCAAGCU3' | 82 | 54.88% | Ki: 2.5 µM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_1 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUGAAUGAGAGAGAAGUAAAAGGUUGAUAUAAAUAGUGCCCA3' | 57 | 42.11% | Kd: 11 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_2 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUUCGAAAGAAAAGAGUAACUGGUUGAUAUAAAUAGUGCCCA3' | 57 | 42.11% | Kd: 10 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_3 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUAAGAGAAGAAGUACCCGAGCGUUGAUAUAAAUAGUGCCCA3' | 57 | 47.37% | Kd: 10 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_4 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUGAUGAAGUAAAAAGCGAUGAGUUGAUAUAAAUAGUGCCCA3' | 57 | 42.11% | Kd: 21 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_5 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUGGGAGGCAGAAAGGAAAAAGUGUUGAUAUAAAUAGUGCCCA3' | 58 | 46.55% | Kd: 13 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_6 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUAAGAAAGAACGGAACCAUGGUUGAUAUAAAUAGUGCCCA3' | 56 | 44.64% | Kd: 10 nM | 1999 |
| Upstream of N-Ras_Jacquemin-Sablon_7 | Unr (Upstream of N-Ras) protein, Human | 5'GGGCCACCAACGACAUUGAAAAAAAAACAAGAAGAAGGUUGAUAUAAAUAGUGCCCA3' | 57 | 38.60% | Kd: 8 nM | 1999 |
| VSG_Göringer_1 | Trypanosome variant surface glycoprotein (VSG) | 5'CGUCCAUCGGGUGGCCCGUGUCUGAGCGGGGACGGGGACUUGAGCGCCGCUGUCCGACUGAAUU3' | 80 | 63.75% | Kd: 60 ± 17 nM | 1999 |
| HIV-1 TAR_Toulmé_1 | Trans-activation responsive (TAR) RNA element of HIV-1 | 5'GGUUACCAGCCUUCACUGCGGGCCACGAUUGUCGAGUCCAUCAACAGGUCCCAGACGUGUUGAACUGGAGAUCCCCCCGCACCACGGUCGGUCACAC3' | 97 | 60.82% | Kd: 30 nM | 1999 |
| HIV-1 TAR_Toulmé_2 | Trans-activation responsive (TAR) RNA element of HIV-1 | 5'GGUUACCAGCCUUCACUGCACAGCCUCACUCCGGUCCCAGACGAAGUGACGGCACCAUGUGAGAAGCCCUACUGUGCCCGCACCACGGUCGGUCACAC3' | 98 | 62.24% | NA | 1999 |
| HIV-1 TAR_Toulmé_3 | Trans-activation responsive (TAR) RNA element of HIV-1 | 5'GGUUACCAGCCUUCACUGCCCAGCGCAAUGACGACCCCCAGUCCCAGAUGGGAGGUCAUAGUCAUAGUCGGACUCACCGCGGCACCACGGUCGGUCACAC3' | 100 | 62.00% | NA | 1999 |
| HIV-1 TAR_Toulmé_4 | Trans-activation responsive (TAR) RNA element of HIV-1 | 5'UCAACACGGUCCCAGACGUGUUGA3' | 24 | 54.17% | Kd: 32 ± 8 nM | 1999 |
| NF-kB_Maher_1 | Human transcription factor NF-kB as a p50 homodimer (p502) | 5'GGGAUAUCCUCGAGACAUAAGAAACAAGAUAGAUCCUGAAACUGUUUUAAGGUUGGCCGAUCUUCUGCUCGAGAAUGCAUGAAGCGUUCCAUAUUUUU3' | 98 | 40.82% | Kd: 1.34 ± 0.2 nM | 1999 |
| 16s-rRNA region_Rando_1 | Prokaryotic 16s-rRNA region | 5'GGGAGAAUUCCGACCAGAAGCCUUCUCCUGCCGCGCGAUUUUACGCCGACAAGGGUGGCAUGAUGAUGUGUCUNUAUAUAGCAUAUGUGCGUCUACAUGGAUCCUCA3' | 106 | 50.94% | Kd: 1.236 ± 0.051 μM | 2000 |
| 16s-rRNA region_Rando_2 | Prokaryotic 16s-rRNA region | 5'GGGAGAAUUCCGACCAGAAGCUUUUAGGGCGGGACUUUUGGCCGCAAAGGUUGGUGUGAGGGUUCUCAAUAAUGGCCCAAGCAUAUGUGCGUCUACAUGGAUCCUCA3' | 107 | 51.40% | Kd: 1.446 ± 0.088 μM | 2000 |
| 16s-rRNA region_Rando_3 | Prokaryotic 16s-rRNA region | 5'GGGAGAAUUCCGACCAGAAGCGGCGUUCCGCAUCGGCAACUGGCGAGGAGUUGUAUUCGGCGGAAACGGGUUGAGGUCCGACAUAUGUGCGUCUACAUGGAUCCUCA3' | 107 | 57.01% | Kd: 1.665 ± 0.101 μM | 2000 |
| 16s-rRNA region_Rando_4 | Prokaryotic 16s-rRNA region | 5'GGGAGAAUUCCGACCAGAAGCAGUGGAAGAGCCGGGUUGGGCAUAUGUGCGUCUACAUGGAUCCUCA3' | 67 | 55.22% | Kd: 2.946 ± 0.149 μM | 2000 |
| 16s-rRNA region_Rando_5 | Prokaryotic 16s-rRNA region | 5'GGGAGAAUUCCGACCAGAAGCAGCGGAACGGCCGACUUCAACAUAUGUGCGUCUACAUGGAUCCUCA3' | 67 | 53.73% | Kd: 2.786 ± 0.188 μM | 2000 |
| Doxycyline_Famulok_1 | Doxycyline | 5'GGAGCUCGGUAGUGACGCGUUGUGUUUACGCGUCUGAUGAGUGUAUAUGACACCGAUGGGUAUUUGCUAGUAUCCUGCGUUCACGAAACUACCUCGAGACGU3' | 102 | 50.00% | Ki: 70 ± 20 nM | 2000 |
| Doxycyline_Famulok_2 | Doxycyline | 5'GGAGCUCGGUAGUGACGCGUUGUGUUUACGCGUCUGAUGAGUGGUACAGUCCAGGGUGAAGUUCCAAUUUUGAACACCUCCACGAAACUACCUCGAGACGU3' | 101 | 51.49% | Ki: 20 ± 5 nM | 2000 |
| Doxycyline_Famulok_3 | Doxycyline | 5'GGAGCUCGGUAGUGACGCGUUGUGUUUACGCGUCUGAUGAGUGGUUUGACCCUUGAUUCGAUGUAUUCGAAAGUGCUUGUUGACGAAACUACCUCGAGACGU3' | 102 | 49.02% | Ki: 25 ± 3 nM | 2000 |
| ATP_Ellington_1 | Adenosine triphosphate (ATP) | 5'GGAAGGCACGACGAAGCAAGCAGGCAACGAACACAGAAGACCGGGGGAACUACCGCGCGUGCCAGACCCAACCAGCCAGAGACC3' | 84 | 63.10% | Kd: 223 μM ± 20 μM | 2000 |
| ATP_Ellington_2 | Adenosine triphosphate (ATP) | 5'GGAAGGCACGACGAAGCAAGCAGGCAACGAACACAGAAGACCGGGGGAACUACCGCGCGCGCCAGACCCAACCAGCCAGAGACC3' | 84 | 64.29% | Kd: 165 μM ± 10 μM | 2000 |
| ATP_Ellington_3 | Adenosine triphosphate (ATP) | 5'GGGCGCGACGAAGCAAGCAGGCAACGAACACAGAAGACCGGGGGAACUACCGCGCGCGCCC3' | 61 | 68.85% | Kd: 175 μM ± 5 μM | 2000 |
| ATP_Ellington_4 | Adenosine triphosphate (ATP) | 5'GGAAGGCACGACCGCGCAAGAUACCGCCCGACAGCGGAAGGAGGGGCAUGCGGUCCAGGGCUGAGACCCAACCAGCCAGAGACC3' | 84 | 67.86% | NA | 2000 |
| Doxycyline_Famulok_4 | Doxycyline | 5'GGAGCUCGGUAGUGACGCGUUGUGUUUACGCGUCUGAUGAGUCCUCGGUAAUCGCCGUAUCAAAAGUCGGAAUGGAGGGUCGACGAAACUACCUCGAGACGU3' | 102 | 53.92% | Ki: 50 ± 30 nM | 2000 |
| Pepocin_Ellington_1 | Pepocin | 5'GGGAGUCUGAAGUCGGACUCGAUAUCAAUUCACUUCAGACU3' | 41 | 46.34% | Kd: 17.9 ± 2.2 nM | 2000 |
| Pepocin_Ellington_2 | Pepocin | 5'GGGAAUGGAUCCACAUCUACGUAUUCAACCAAGUCUAAUGUCGGACUCGAUAUCAAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 43.75% | Kd: 21.0 ± 2.0 nM | 2000 |
| Pepocin_Ellington_3 | Pepocin | 5'GGGAAUGGAUCCACAUCUACGUAUUCAGUCUAGGAAGCAGUCGGACUUGUUAUCAAUUCACUGCAGACUGUACGAAGCUU3' | 80 | 45.00% | Kd: 23.4 ± 2.3 nM | 2000 |
| cAMP_Breaker_1 | Second messenger adenosine 3',5'-cyclic monophosphate (cAMP; 1) | 5'GGAAGAGAUGGCGACUAAAACGACUUGUCGCGUGCUGCCCGCCUGUUCGCUUCUGCACCCCGGCGGUAAGCUUGGCAC3' | 78 | 61.54% | No reported | 2000 |
| cAMP_Breaker_2 | Second messenger adenosine 3',5'-cyclic monophosphate (cAMP; 1) | 5'GGAAGAGAUGGCGACUAAAACGACUUGUCGC3' | 31 | 51.61% | Kd: 10 μM | 2000 |
| R5 helix peptide_Okahata_1 | R5 helix peptide | 5'GGGAAACUGGAUGGAAUGGGCUCGAUGAAAAUCGACCGUGCGCUGAAAAGCACGCGAGGUCCUGCUGUAAGUGUGCCA3' | 78 | 55.13% | Kd: 10 nM | 2000 |
| R5 helix peptide_Okahata_2 | R5 helix peptide | 5'GGGAAACUGGAUGGAAUGGGCUCGCAAGGCCCCCUGAGCUGCACAAGUUCAUGGCGAGGUCCUGCUGUAAGUGUGCCA3' | 78 | 58.97% | Kd: 10 nM | 2000 |
| L-tyrosine_Tocchini-Valentini_1 | L-tyrosine | 5'GGGAAGCUUGUACAGGGGGCAGUCAACUCGUGCGAUCGUGAAAACGGGGCAAGAUGGCCUUACAGCGGUCAAUACGGGGGUCAUCAGAUAGGGAGGCCCUCCUGGUGGUCCGUUCGGGAUCCUC3' | 124 | 59.68% | Kd: 35 μM | 2000 |
| HCV NS3_Nishikawa_1 | Nonstructural protein 3 (NS3) protease active site in the truncated polypeptide ΔNS3, Hepatitis C virus (HCV) | 5'GGGAGAAUUCCGACCAGAAGCUUCGGGAUUUGAGGGUAGAAUGGGACUACCUUUCCUCUCUCCUUCCUCUUCU3' | 73 | 50.68% | Kd: 11.6 nM | 2000 |
| HCV NS3_Nishikawa_2 | Nonstructural protein 3 (NS3) protease active site in the truncated polypeptide ΔNS3, Hepatitis C virus (HCV) | 5'GGGAGAAUUCCGACCAGAAGUGCUCUUAGAAUGGGACUAAGACACGGGACCCUUUCCUCUCUCCUUCCUCUUCU3' | 74 | 51.35% | Kd: 6.3 nM | 2000 |
| HCV NS3_Nishikawa_3 | Nonstructural protein 3 (NS3) protease active site in the truncated polypeptide ΔNS3, Hepatitis C virus (HCV) | 5'GGGAGAAUUCCGACCAGAAGUACGACACGAUUGGGACGUGUCUAUGGGACCCUUUCCUCUCUCCUUCCUCUUCU3' | 74 | 52.70% | Kd: 8.9 nM | 2000 |
| HIV-1 Tat protein_Sugimoto_1 | Tat protein from HIV-1 in the presence of Zn2+ ion | 5'GGGAGAAUUCCGACCAGAAGCUUUGGUUAUCAUGUUUAUGCGUACGGGCGCCCAUAUGUGCGUCUACAUGGAUCCUCA3' | 78 | 50.00% | Kd: 0.31 μM | 2000 |
| WT1-ZFP_Romaniuk_1 | WT1-ZFP & WT1[+KTS]-ZFP (two zinc finger isoforms of the WT1 DNA binding domain) | 5'GGGGCCACCAACGACAUUGACGAAUGCGUAAAUUGCUAGGUUGAUAUAAAUAGUGCCCAUGGAUCCGCGGGUGUCGGG3' | 78 | 52.56% | Kd: 87.4 ± 10.4 nM (WT1-ZFP) & 69.8 ± 8.4 nM (WT1[+KTS]-ZFP) | 2001 |
| WT1-ZFP_Romaniuk_2 | WT1-ZFP & WT1[+KTS]-ZFP (two zinc finger isoforms of the WT1 DNA binding domain) | 5'GGGGCCACCAACGACAUUGAUAUGGUGACCACCCCGGCGUUGAUAUAAAUAGUGCCCAUGGAUCCGCGGGUGUCGGG3' | 77 | 58.44% | Kd: 13.8 ± 1.1 nM (WT1-ZFP) & 22.8 ± 2.3 nM (WT1[+KTS]-ZFP) | 2001 |
| WT1-ZFP_Romaniuk_3 | WT1-ZFP & WT1[+KTS]-ZFP (two zinc finger isoforms of the WT1 DNA binding domain) | 5'GGGGCCACCAACGACAUUAUCACCCACCCCGAGCUGGCGUUGAUAUAAAUAGUGCCCAUGGAUCCGCGGGUGUCGGG3' | 77 | 59.74% | Kd: 17.8 ± 1.4 nM (WT1-ZFP) & 33.7 ± 4.4 nM (WT1[+KTS]-ZFP) | 2001 |
| sLeX_Yu_1 | Sialyl Lewis X (sLeX)-expressing HL60 cells | 5'CCGUAAUACGACUCACUAUAGGGGAGCUCGGUACCGAAUUCAAGGYACUCUGUGCUUGUCGAUGUGYAUUGAUGGCACUUUCGAGUCAACGAGUUGACAGRACAAGUAGUCAAGCUUUGCAGAGAGGAUCCUU3' | 130 | 46.62% | Kd: 0.085 nM and 3.3 nM via SPR | 2001 |
| tetracyclins_Schroeder_1 | Class I typical tetracyclins | 5'GCAUGCUAAUACGACUCACUAUAGGAGCUCAGCCUUCACUGCUGCUUAAAGCCUAAAACAUACCAGAUCGCCACCCGCGCUUUAAUCUGGAGAGGUGAAGAAUUCGACCACCUAGGCUGCACCACAAGCUU3' | 131 | 49.62% | Kd: ~1 μM | 2001 |
| tetracyclins_Schroeder_2 | Class I typical tetracyclins | 5'GGCCUAAAACAUACCAGAUUUCGAUCUGGAGAGGUGAAGAAUUCGACCACCUAGGCCGGU3' | 60 | 50.00% | NA | 2001 |
| Sephadex G-100_Engelke_1 | Sephadex G-100 | 5'GGGAGUCGACCGACCAGAAGUCCGAGUAAUUUACGUUUUGAUACGGUUGCGGAACUUGCUAUGUGCGUCUACAUCUAGACUCAU3' | 84 | 47.62% | NA | 2001 |
| Thrombin_Sullenger_1 | Thrombin, Human and porcine | 5'GGGAGAGAGGAAGAGGGAUGGGGAACAAAGCUGAAGUACUUACCCAAGAUCAUCCCGAACGACAUAACCCAGAGGUCGAU3‘ | 80 | 51.25% | Kd: (Human: 2.8 ± 0.7 nM, Porcine: 83 ± 3 pM) | 2001 |
| Adenine_Maurel_1 | Adenine | 5'GGGAGAGGAUACUACACGUGAUAGGACGAUUAUCGAAAAUCACCAGAUUGGACCCUGGUUAACGAUCCAUUGCAUGUAGCAGAAGCUUCCG3' | 91 | 47.25% | Kd: 10 μM | 2001 |
| N6-adenine_Maurel_1 | N6-adenine | 5'GCGAAUUCGGAGAGGAUACUACACGUGAUAGGACGAUUAUCGAAAAUCACCAGAUUGGACCCUGGUUAACGAUCGGAAGCUUCUGCUACAUGCAAUGG3' | 98 | 46.94% | Kd: 10 μM | 2002 |
| HCV NS5B_Tomei_1 | Nonstructural 5B (NS5B) polymerase, hepatitis C virus (HCV) NS5BΔC55 protein | 5'GGGAUGCUUCGGCAUCCCAGUCGAUGCGUAUCGCAGACUAUGUGGCUUCGGCCGUUGGAGUUGGUACCGCUUCGGCGGUACGUAAGCUUGGG3' | 92 | 59.78% | Kd: 16 ± 1.6 nM | 2002 |
| HCV NS5B_Tomei_2 | Nonstructural 5B (NS5B) polymerase, hepatitis C virus (HCV) NS5BΔC55 protein | 5'GGGAUGCUUCGGCAUCCCCGAAGCCGCUAUGGACCAGUGGCGCGGCUUCGGCCCGACGGAGUGGUACCGCUUCGGCGGUACGUAAGCUUGGG3' | 92 | 67.39% | Kd: 1.5 ± 0.2 nM | 2002 |
| HCV NS5B_Tomei_3 | Nonstructural 5B (NS5B) polymerase, hepatitis C virus (HCV) NS5BΔC55 protein | 5'GGGAUGCUUCGGCAUCCCGCUCUGGGCCGAAUAUGGACCACGUGGCUUCGGCCGCCAGCUCGUGUACCGCUUCGGCGGUACGUAAGCUUGGG3' | 92 | 65.22% | Kd: 10 ± 1.6 nM | 2002 |
| HCV NS5B_Tomei_4 | Nonstructural 5B (NS5B) polymerase, hepatitis C virus (HCV) NS5BΔC55 protein | 5'CGAAGCCGCGCUAUGGACCAGUGGCGCGGCUUCG3' | 34 | 70.59% | Kd: >>200 nM | 2002 |
| Streptavidin_James_1 | Streptavidin (SA) | 5'AAUUAACCCUCACUAAAGGGAACUGUUGUGAGUCUCAUGUCGAACUUUCCUAGCGCACAUGCGACCUCUAUGCGUAAUACGAACGUUGACGGUUUGAGCGUCUAGUCUUGUCU3' | 113 | 46.02% | Kd: 7 ± 1.8 nM | 2002 |
| Neuropeptide Y_Famulok_1 | Neuropeptide Y (NPY) | 5'UCGGAGAAAGGGAAGCUUGAGCAGCAGGAGGGCCGGCGUUAGGGUUAGCGAGCCGAUUGAAAGAAGAAGGAACGAGCGUACGGAUCCGAUC3' | 91 | 57.14% | Kd: 0.37 μM | 2002 |
| C5 protein_Lee_1 | Complement 5 protein (C5 protein) | 5'CGUCCCUUCGCAACCCUUUAAGACUUGGGACCCUGCUCUU3' | 40 | 55.00% | Kd: 3.6 nM | 2002 |
| T. thermophilus RF1_Sprinzl_1 | Release factor 1 (RF1), Thermus thermophilus (T. thermophilus) | 5'GGGAGAGGAUACUACACGUGGUGUGUCAAGCCAGCCCUAGCUUGCUACCUGGGGGCCACUGACCUAUCCAUUGCAUGUAGCAGAAGCUUCCG3' | 92 | 56.52% | Kd: 2 x 10^-5 M | 2002 |
| T. thermophilus RF1_Sprinzl_2 | Release factor 1 (RF1), Thermus thermophilus (T. thermophilus) | 5'GGGAGAGGAUACUACACGUGGAAAGCUGAAAGUGAACGGAGUAUCACAGAGAACCCGGAAAAGUGGAGCCAUUGCAUGUAGCAGAAGCUUCCG3' | 93 | 50.54% | Kd: 2 x 10^-5 M | 2002 |
| NFATc DBD_Lee_1 | Nuclear factor of activated T cells NFATc DNA binding domain (DBD) | 5'GGGAGAGCGGAAGCGUGCUGGGCCUCUGUUCCCAAGGGAAUACYGGUCGUGUUGGAUCAGGUUGGCAUAACCCAGAGGUCGAUGGAUCCCCCC3' | 92 | 60.87% | Kd: 30 nM | 2002 |
| ATP_Burke_1 | ATP | 5'GGGAAAAGCGAAUCAUACACAAGACUUAGGAGGAAGAAACUGCACAAUACACAGAUCACGCGAAAGGAUAAUGCGUUCUGCGGAUUGUGGGCCUGGGCAUAAGGUAUUUAAUUCCAUA3' | 118 | 44.07% | NA | 2002 |
| ATP_Burke_2 | ATP | 5'GGGAAAAGCGAAUCAUACACAAGAGCAAUCUUGUUAACGGUGGAGGACGUAUGAAGGAAACUUAGGAAUCCCUGGUCCACGAAUCUGACCGUGUGGGCAUAAGGUAUUUAAUUCCAUA3' | 118 | 44.07% | NA | 2002 |
| ATP_Burke_3 | ATP | 5'GGGAAAAGCGAAUCAUACACAAGAAAGAACGUGAUGAAACGGUAACCAUAUCGCGUGCUCAAACUACAACGGAAAAUGAGGAGGAACGUGCUCAUGGGCAUAAGGUAUUUAAUUCCAUA3' | 119 | 42.02% | NA | 2002 |
| ATP_Burke_4 | ATP | 5'GGGAAAAGCGAAUCAUACACAAGAUUCACUCUACACCCAUGUCCCUAGGACUACAGGUUAACUACAAACCUCGAUCCGGUGCUUAGGGUGUGCUGG3' | 100 | 0 | NA | 2002 |
| E2F_Sullenger_1 | E2F transcription factor | 5'GUCGAUGUGAUAAGUAGGACGGAGGUGGUCGAU3' | 33 | 51.52% | Kd:2–4 nM | 2002 |
| Beta amyloid peptide_Fürste_1 | Beta amyloid peptide (βA4(1–40)) | 5'UUACCGUAAGGCCUGUCUUCGUUUGACAGCGGCUUGUUGACCCUCACACUUUGUACCUGCUGCCAA3' | 66 | 51.52% | Kd: 29–48 nM | 2002 |
| GTP_Szostak_1 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGAUGCUCAACAGUAGCCAACACGAGUACUGCUUCGGCAGUGGAACCAACGUAGUAUGUUUAGCAUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 122 | 47.54% | Kd: 28 nM | 2002 |
| GTP_Szostak_2 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGACUUUCCGaAGuGGUUGGGCUGCUUCGGCAGuGuGAAAaCGGAGAGUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 105 | 50.48% | Kd: 60–300 nM | 2002 |
| GTP_Szostak_3 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGAGAUAAGUUCCCAAGGCGGGUUGGAAGAGAUAUCAUAGGAGCUUGUCUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 106 | 47.17% | Kd: 200 nM | 2002 |
| GTP_Szostak_4 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGAUCUAGCAGUUCAGGUAACCACGUAAGAUACGGGUCUAGAUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 99 | 46.46% | Kd: 250 nM | 2002 |
| GTP_Szostak_5 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGAGGCAUCUAUAUACUGCUUCGGCAGGGAACUCUACUAAGCACCGAUGUCUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 108 | 48.15% | Kd: 250 nM | 2002 |
| GTP_Szostak_6 | Guanosine triphosphate (GTP) | 5'GUGACGCGACUAGUUACGGAAAUGAAGAUAGUCGGGACCACUUCCCUGAGUCUGCUUCGGCAGUAACUCCAAGGAGAAAGGUCGUCAUUUUCAUUCAGUUGGCGCCUCCUAUAGUGAGUCGUAUUACAU3' | 129 | 48.06% | Kd: 500 nM | 2002 |
| Mitochondria_Adhya_1 | Mitochondria | 5'GGAAUUCUAAUACGACUCACUAUAGGGACGCAGGGACUGUACCUUCUAGGCUGGGUCAUGUGACUGUAGCGG3' | 72 | 51.39% | Kd: 1 nM | 2002 |
| Mitochondria_Adhya_2 | Mitochondria | 5'GGAAUUCUAAUACGACUCACUAUAGGGACGCAGGGACUGUACGGUAAGUCCCCGGGCAUGUGACUGUAGCGG3' | 72 | 54.17% | Kd: 0.46 nM | 2002 |
| Mitochondria_Adhya_3 | Mitochondria | 5'GGAAUUCUAAUACGACUCACUAUAGGGACGCAGGGACUGUAUGGUUUUCUGGGGUUUAUGUGACUGUAGCGG3' | 72 | 47.22% | Kd: 1.19 nM | 2002 |
| Mitochondria_Adhya_4 | Mitochondria | 5'GGAAUUCUAAUACGACUCACUAUAGGGACGCAGGGACUGUACGGAUCAGAGUCUCCUAUGUGACUGUAGCGG3' | 72 | 50.00% | Kd: 0.1 nM | 2002 |
| NTS-1_Grisshammer_1 | Rat neurotensin receptor NTS-1 | 5'UAAUACGACUACUAUAGGGAGGACGAUGCGGACAGAUACGGAACUACAGAGGUCAAUUACGGUGGCCACGCCAGACGACUCGCCCGA3' | 87 | 54.02% | Kd: 0.37 nM | 2002 |
| HCV NS5B_Lai_1 | Hepatitis C virus NS5B protein (HCV NS5B protein) | 5'GGGAGCUCAGAAUAAACGCUCAACUCCUAACCUCUCCGCAUGNGCUGUUACCUACACAGCUCAGCAUGCAUGAGGCCCGGAUCCGGC3' | 86 | 56.98% | Kd: 100 ± 6 (1/s) | 2003 |
| HCV NS5B_Lai_2 | Hepatitis C virus NS5B protein (HCV NS5B protein) | 5'GGGAGCUCAGAAUAAACGCUCAAUGUAGAGACUUUUCGAAAAGCGUGUUCCCAAUGAGUCUAUGCAUGCAUGAGGCCCGGAUCCGGC3' | 87 | 50.57% | Kd × 10e4: 1.0 ± 0.1 (1/s) | 2003 |
| HCV NS5B_Lai_3 | Hepatitis C virus NS5B protein (HCV NS5B protein) | 5'GGGAGCUCAGAAUAAACGCUCAAUGUAGGCUAGUACCGACCUGCGUGCCUCGCUCCUUUUCAUGCAUGCAUGAGGCCCGGAUCCGGC3' | 87 | 57.47% | Kd × 10e4: 100 ± 6 (1/s) | 2003 |
| Angiopoietin-2_Sullenger_1 | Angiopoietin-2 (Ang2) | 5'GGGAGGACGAUGCGGACUAGCCUCAUCAGCUCAUGUGCCCCUCCGCCUGGAUCACCAGACGACUCGCUGAGGAUCCGAGA3' | 80 | 62.50% | Kd: 3.1 nM | 2003 |
| Angiopoietin-2_Sullenger_2 | Angiopoietin-2 (Ang2) | 5'GAGGACGAUGCGGACUAGCCUCAUCAGCUCAUGUGCCCCUC3' | 41 | 60.98% | Kd: 2.2 nM | 2003 |
| Thrombin_Shao_1 | Thrombin, Bovine | 5'GCAAUGGUACGGUACUUCCUUUGGAAGAUAGCUGGAGAACUAACCAAAAGUGCACGCUACUUUGCUAA3' | 68 | 44.12% | Kd: 164 nM | 2003 |
| Thrombin_Shao_2 | Thrombin, Bovine | 5'GCAAUGGUACGGUACUUCCAAGUGCGGGGGGGAGGUGGUGGUUCCAAAAGUGCACGCUACUUUGCUAA3' | 68 | 54.41% | Kd: 240 nM | 2003 |
| HER3ECD_Landgraf_1 | Oligomeric state of the extracellular domains of human epidermal growth factor receptor-3 (HER3ECD) | 5'GGGAAUUCCGCGUGUGCCAGCGAAAGUUGCGUAUGGGUCACAUCGCAGGCACAUGUCAUCUGGGCGGUCCGUUCGGGAUCCUC3' | 83 | 60.24% | Kd: 45 nM in hrg-unbound; 400 nM in hrg-bound | 2003 |
| eIF4A_Nakamura_1 | Mammalian translation initiation factor 4A (eIF4A) | 5'GGGAGACAAGAAUAAAACGCUCAAACAUUGCAUCGACAGCUGCAAGGCUCCCGCCGUACAAACCUUCGACAGGAGGCUCACAACAGGC3' | 88 | 53.41% | Kd: 8 μM | 2003 |
| eIF4A_Nakamura_2 | Mammalian translation initiation factor 4A (eIF4A) | 5'GGGAGACAAGAAUAAAACGCUCAACAGGCGUUUAGCCUCUAAGUAACAGGGGCCUCCCAUGAGCUUCGACAGGAGGCUCACAACAGGC3' | 88 | 53.41% | Kd: 3 μM | 2003 |
| eIF4A_Nakamura_3 | Mammalian translation initiation factor 4A (eIF4A) | 5'GGGAGACAAGAAUAAAACGCUCAAGGGGACCGCGCCCCACAUGUGAGUGAGGCCGAAACGUAGAUUCGACAGGAGGCUCACAACAGGC3' | 88 | 56.82% | Kd: 44 nM | 2003 |
| eIF4A_Nakamura_4 | Mammalian translation initiation factor 4A (eIF4A) | 5'GGGAGACAAGAAUAAAACGCUCAAUGUGGAUGAUUUGUAUGAUCGCGCAUACAAUUCGACAGGAGGCUCACAACAGGC3' | 78 | 46.15% | Kd: 1 μM | 2003 |
| eIF4A_Nakamura_5 | Mammalian translation initiation factor 4A (eIF4A) | 5'GGGAGACAAGAAUAAAACGCUCAAGGGGACCGCGCCCCACAUGUGAGUGAGGCCGAAACAUAGAUUCGACAGGAGGCUCACAACAGGC3' | 88 | 55.68% | Kd: 27 nM | 2003 |
| ATP_Guo_1 | ATP (Adenosine triphosphate) | 5'UCAAUGGUACGGUACUUCCAUUGUCAUGUGUAUGUUGGGGAUUAAACCCUGAUUGAGUUCAGconCCCACAUACUUUGUUGAUUGGUUGUCAAUCAUGGCAAAAGUGCACGCUACUUUGA3' | 118 | 42.37% | Kd: 1.3 ± 0.8 mM | 2003 |
| ATP_Guo_2 | ATP (Adenosine triphosphate) | 5'UCAAUGGUACGGUACUUCCAUUGUCAUGUGUAGGGUUGGGAAGAAACUGUGGCACUUCGGUGCCAGconCAACCCUACUUUGUUGAUUGGUUGUCAAUCAUGGCAAAAGUGCACGCUACUUUGA3' | 122 | 46.72% | Kd: 0.1 ± 0.06 mM | 2003 |
| MAb198 antibody_Lee_1 | MAb198 antibody, Rat | 5'GGGCCGGAGGUUAGCUUGCCCAUGGCAAGCAGGGCGCCACGGACCC3' | 46 | 71.74% | Kd: 30 nM | 2003 |
| 4,4′-methylenedianiline_Labuda_1 | 4,4′-methylenedianiline (MDA) | 5'GCCUGUUGUGAGCCUCCUGUCGAACUGCGAUCAGCGGUAAAUUUCCGCGCAGCCUCCACGCCGCUUGAGCGUUUAUUCUUGUCUCCC3' | 87 | 57.47% | Kd: 0.45 μM | 2004 |
| 4,4′-methylenedianiline_Labuda_2 | 4,4′-methylenedianiline (MDA) | 5'GCCUGUUGUGAGCCUCCUGUCGAACAGAGGCAGUACUCAUCAACCCGAGCCUUCCGUCCCUGAGUUGAGCGUUUAUUCUUGUCUCCC3' | 87 | 55.17% | Kd: 2 μM | 2004 |
| 4,4′-methylenedianiline_Labuda_3 | 4,4′-methylenedianiline (MDA) | 5'GCCUGUUGUGAGCCUCCUGUCGAAUGGGAGGAGUGCUGCUCUCCAGGCACUCUUGUUGCUCGGAUUGAGCGUUUAUUCUUGUCUCCC3' | 87 | 55.17% | Kd: 12 μM | 2004 |
| NFAT DBD_Lee_1 | Nuclear factor of activated T cells DNA binding domain (NFAT DBD) | 5'GGGAGAGCGGAAGCGUGCUGGGCCGAUAUGAAGGAGUGGAGAGGGUGGCAGCAUGGUCCGGAUCCAUAACCCAGAGGUCGAUGGAUCCCCCC3' | 92 | 63.04% | Kd: 11.1 nM | 2004 |
| NFAT DBD_Lee_2 | Nuclear factor of activated T cells DNA binding domain (NFAT DBD) | 5'GGGAGAGCGGAAGCGUGCUGGGCCGAGGGAGGCGAUAUGAAGGUGUAGAGAGGCCUCCUGGACACAUAACCCAGAGGUCGAUGGAUCCCCCC3' | 92 | 63.04% | Kd: 120 nM | 2004 |
| CRD of colicin E3_Yokoyama_1 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUACUGUCCUCCCUUCAGAGAGCGCGGGACCCUUAACUUGGGGCCCACGAACAGCUUCAGUUCCGUCUCGGCGUCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 121 | 56.20% | Kd: 2±11 nM | 2004 |
| CRD of colicin E3_Yokoyama_2 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUUCCCUGGCCCAAGAUCCUAAUAAAGUUUUUUCGGACCGGAGCGAAACCACUAUCCUCUUAAGCAAUCUGUCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 119 | 47.06% | Kd: 14±2 nM | 2004 |
| CRD of colicin E3_Yokoyama_3 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUGUACAACACAUCAUUACGGCUGCUAUUGGCUCCAAGCGUCUUUCUCCCUGGUCAAUAGUCCAGCCACCACGCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 120 | 50.83% | Kd: 4±15 nM | 2004 |
| CRD of colicin E3_Yokoyama_4 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUGACAUCUGUAAGUAAGAUUCUAUCUGCAAAGCGGUUAGGAGGGCUCGGACUCUGAUUGCCUCCCCGCACCCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 119 | 51.26% | Kd: 7±1 nM | 2004 |
| CRD of colicin E3_Yokoyama_5 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUGACAUCUGUAAGUAAGAUUCUAUCUGCAAAGCGGUUAGGGGGGCUCGGACUCUGAUUGCCUCCCCGCACCCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 119 | 52.10% | Kd: 294±170 nM | 2004 |
| CRD of colicin E3_Yokoyama_6 | C-terminal ribonuclease domain of colicin E3 (CRD of colicin E3) | 5'GGGAGAAUUCCGACCAGAAGCUUGUCAGCUGCUCGCGGGAUCGAUCCAUUCGGUGGCCAUGCUCCGGAAGACGGGCCGGCUUCGCAAGACUCAGGCAUAUGUGCGUCUACAUGGAUCCUCA3‘ | 121 | 58.68% | Kd: 10±1 nM | 2004 |
| RANK_Nakamura_1 | Receptor activator of NF-kappaB (RANK), Human | 5'ACACAAUGGACGGAUUCGUAUGGGUGGGAUCGGGAAGGGCUACGAACACCGUAACGGCCGACAUGAGAG3' | 69 | 56.52% | Kd: 0.33 μM | 2004 |
| RANK_Nakamura_2 | Receptor activator of NF-kappaB (RANK), Human | 5'ACACAAUGGACGAUAUGGUAUUGAGGUGGGAAGGGGAUUGGGAUAAUUGCCAUAACGGCCGACAUGAGAG3' | 70 | 48.57% | Kd: 1.8 μM | 2004 |
| RANK_Nakamura_3 | Receptor activator of NF-kappaB (RANK), Human | 5'ACACAAUGGACGAUAGUGGUUGGGAUUGGGUGGGCGCACAAGUUGUUCCGUUAACGGCCGACAUGAGAG3' | 69 | 53.62% | Kd: 5.8 μM | 2004 |
| hTNFα_Zhang_1 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACCCCGGGUUCUGUAUGAUCCGACCGGUCAGAUAAGACCACAAGAAGACUCGCAAGA3' | 71 | 53.52% | NA | 2004 |
| hTNFα_Zhang_2 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGCAUCGUUUGCGUGGCGUGUCCGGGCGCCGAUUCGUAAAAAGAAGACUCGCAAGA3' | 71 | 56.34% | NA | 2004 |
| hTNFα_Zhang_3 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACUAGGCGGAUUGUUUCGAUUCUUUGCCUUGUCCCUAGUGCAAGAAGACUCGCAAGA3' | 71 | 49.30% | NA | 2004 |
| hTNFα_Zhang_4 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGUAUAUACGGAUUAGGUUGUAGCUCAGACCAGUAAUGUCAAGAAGACUCGCAAGA3' | 71 | 45.07% | NA | 2004 |
| hTNFα_Zhang_5 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGUGCUAGAUGCUACGAGUGGUCUCCUCACGUAGAAGGGGAAGAAGACUCGCAAGA3' | 71 | 53.52% | NA | 2004 |
| hTNFα_Zhang_6 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAGGUCCCACAUAGGUUGGUCUUGUUGUAUGGGCUGUUUGCAAAGAAGACUCGCAAGA3' | 71 | 49.30% | NA | 2004 |
| hTNFα_Zhang_7 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAGUGUUUUGGGAGAGAAAAGGGGGAGCCUUUACUUUGUUGGAAGAAGACUCGCAAGA3' | 71 | 47.89% | NA | 2004 |
| hTNFα_Zhang_8 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAGACGAUGUUAUCAGGGAGUUGGGAUCAUAUAGUCUUACAUAAGAAGACUCGCAAGA3' | 71 | 43.66% | NA | 2004 |
| hTNFα_Zhang_9 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGCAAGAGCCGCCCUAAUGGUUCAAUGGUAACUGUAUAUGAAGAAGACUCGCAAGA3' | 71 | 47.89% | NA | 2004 |
| hTNFα_Zhang_10 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAGACUUCUUGUGCCAUUAUGAAUUAUUGCUAAUCCUCUUGAAAGAAGACUCGCAAGA3' | 71 | 40.85% | NA | 2004 |
| hTNFα_Zhang_11 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAAGGACGUACUUGGAAAAGAGGCGCGAAGAACCUGGUAUGUAAGAAGACUCGCAAGA3' | 71 | 49.30% | NA | 2004 |
| hTNFα_Zhang_12 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAUAGGACGUACUUGGAAAAGAGGCGCGAAGAACCUGGUAUGAAGAAGACUCGCAAGA3' | 71 | 49.30% | NA | 2004 |
| hTNFα_Zhang_13 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAUGGCCACCUUGCCACUCUUCCUUGCAUAUUUUACUCCCGCAAGAAGACUCGCAAGA3' | 71 | 50.70% | NA | 2004 |
| hTNFα_Zhang_14 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACAAGCCGAGGGGGAGUAUCUGAUGACAAUUCGGAGCUCCAAAGAAGACUCGCAAGA3' | 71 | 52.11% | NA | 2004 |
| hTNFα_Zhang_15 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAUCAUGGUGUGUGAGUUAGCUCACGUGCCGUUUCGAAGGCGAAGAAGACUCGCAAGA3' | 71 | 52.11% | NA | 2004 |
| hTNFα_Zhang_16 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACAUGGGCUAGACCGGCAUAAAACUGCUGUAGUUGCACGCCAAGAAGACUCGCAAGA3' | 71 | 52.11% | NA | 2004 |
| hTNFα_Zhang_17 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGUUGUAGUAGUGGCUUGGGCAUAACUCAGUUAAACACUAAAGAAGACUCGCAAGA3' | 71 | 45.07% | NA | 2004 |
| hTNFα_Zhang_18 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUAGACCGCGGAAAAGGAAGGAAUUAGAUACAACGGAGAAGUGAAGAAGACUCGCAAGA3' | 71 | 47.89% | NA | 2004 |
| hTNFα_Zhang_19 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGCAUCGUUUGCGUGGCGUGUCCGGGCGCAAGAAGACUCGCAAGA3' | 60 | 60.00% | NA | 2004 |
| hTNFα_Zhang_20 | Tumor necrosis factor alpha (hTNFα), Human | 5'GGGAGGACGAUGUUACGUAUAUACGGAUUAGGUUGUAGCUCAGACCAAGAAGACUCGCAAGA3' | 62 | 46.77% | NA | 2004 |
| ARNO/cytohesin-2_Famulok_1 | ADP-ribosylation factors (ARF) nucleotide-binding site opener (ARNO)/cytohesin-2 | 5'GGGAGAGACAAGCUUGGGUCGCGUUUUGCUAUUGAUUUCUUUUAACCUGGCCUGUUUGGGCCUCUUGCUCUUCCUAGGAGU3' | 81 | 49.38% | Kd: 115 ± 3 nM | 2004 |
| TCF-1_Jeong_1 | T-Cell Factor-1 (TCF-1) protein | 5'GGGGAGCUCGGUACCGGUGCGAUCCCCUGUUUACAUUGCAUGCUAGGACGACGCGCCCGAGCGGGUACCCAUUGUGUCGUCGGAAGCUUUGCAGAGGAUC3' | 100 | 61.00% | Kd: 100~500 nM | 2004 |
| RPKPQQFFGLM-NH2_Klussmann_1 | RPKPQQFFGLM-NH2 (peptide, Substance P ) | 5'GGAGCUUAGACAACAGCAGCGUGCAGGUGGGUAAAGGGGUGUGAUCGAGGGUCGAGAGGCACGCUCAGGUGAGUCGGUUCCAC'3 | 83 | 60.24% | NA | 2005 |
| RPKPQQFFGLM-NH2_Klussmann_2 | RPKPQQFFGLM-NH2 (peptide, Substance P ) | 5'GGCGCAGGUGGGUAAAGGGGUGUGAUCGAGGGUCGAGAGGCGCC3' | 44 | 68.18% | Kd: 40 nM | 2005 |
| TFKBP*3R-2G_Verdine_1 | TFKBP*3R-2G (cell surface protein) | 5'GGGUUCGAAUGCAAGUCUGGUGAGUGUUGGGAGGGCAGUGACUUGCUUCGUAGUGUAAACUGACGUGGCGGUGUUACUUUACUGUUACGCUAGGUUACGGG3' | 101 | 51.49% | Kd: 4.3 ± 0.5 nM | 2005 |
| TFKBP*3R-2G_Verdine_2 | TFKBP*3R-2G (cell surface protein) | 5'CGAAUGCAAGUCUGGUGAGUGUUGGGAGGGCAGUGACUUGCUUCG3' | 45 | 55.56% | Kd: 2.8 ± 0.2 nM | 2005 |
| TFKBP*3R-2G_Verdine_3 | TFKBP*3R-2G (cell surface protein) | 5'GCAAGUCUGGUGAGUGUUGGGAGGGCAGUGACUUGC3' | 36 | 58.33% | Kd:16.1 ± 3.6 nM | 2005 |
| mCXCL10_Gearing_1 | IFN-gamma-inducible (IFN-γ-Inducible) mCXCL10 Chemokine (also known as IP-10 in humans and CRG-2 in mice) | 5'UAAUACGACUCACUAUAGGGAGGACGAUGCGGCAUGCGUCUGACCUACGUGCCAAGCAUUUGUGUAACCCGUCAGACGACUCGCCCGA3' | 88 | 54.55% | Kd: 3.5 nM, IC50 = 40.2 nM | 2005 |
| mCXCL10_Gearing_2 | IFN-gamma-inducible (IFN-γ-Inducible) mCXCL10 Chemokine (also known as IP-10 in humans and CRG-2 in mice) | 5'UCUGACCUACGUGCCAAGCAUUUGUGUAACCCGUCAGA3' | 38 | 50.00% | IC50 = 29.3 nM | 2005 |
| mCXCL10_Gearing_3 | IFN-gamma-inducible (IFN-γ-Inducible) mCXCL10 Chemokine (also known as IP-10 in humans and CRG-2 in mice) | 5'UAAUACGACUCACUAUAGGGAGGACGAUGCGGAGUUUCUUCUGAGGUCUGAACCUUUCGAAAGCUGGCGCUCAGACGACUCGCCCGA3' | 87 | 52.87% | Kd: 1.53 nM | 2005 |
| mCXCL10_Gearing_4 | IFN-gamma-inducible (IFN-γ-Inducible) mCXCL10 Chemokine (also known as IP-10 in humans and CRG-2 in mice) | 5'UAAUACGACUCACUAUAGGGAGGACGAUGCGGACUGAACCUAAUUUGAAAUUGGCUGGCGCGCAUAUUCCGUCAGACGACUCGCCCGA3' | 88 | 51.14% | Kd: 1.76 nM | 2005 |
| HSV-1 US11_Coen_1 | Herpes simplex virus-1 (HSV-1) US11 | 5'GGGAAUGGAUCCACAUCUACGAAUUCGCAAUCCUGUAUUGAACUUCUCACUAAAACUUCACUGCAGACUUGACGAAGCUU3' | 80 | 42.50% | Kd: 70 nM | 2005 |
| CsrA_Babitzke_1 | Carbon storage regulation protein A, Escherichia coli (CsrA of E. coli) | 5'ACCGAGUCCAGAAGCUUGUAGUACACAAGGAUGUGCCAUGCCUAGAUGGAGUUGAAUUCUCCCUAUAGUGAGUCGUAUUAC3' | 81 | 45.68% | Kd: 7.1 ± 0.8 nM | 2005 |
| eIF4E_Nakamura_1 | Mammalian eukaryotic translation initiation factor 4F (eIF4E) | 5'GGGAGACAAGAAUAAACGCUCAAUGUUCAACCAGAGUGAAACCACUAACGGGUCAGAGCCCCUUCGACAGGAGGCUCACAACAGGC3' | 86 | 52.33% | Kd: 11.2 nM | 2005 |
| eIF4E_Nakamura_2 | Mammalian eukaryotic translation initiation factor 4F (eIF4E) | 5'GGGAGACAAGAAUAAACGCUCAAGCCAGAGCAACAACCUUCCGAGCCGCGGGAUAAAACCGAGUUCGACAGGAGGCUCACAACAGGC3' | 87 | 55.17% | NA | 2005 |
| pre-PilS_Wu_1 | Type IVB pili of Salmonella enterica (S. enterica) serovar Typhi (pre-PilS) | 5'GCGGAAUUCUAAUACGACUCACUAUAGGGAACAGUCCGAGCCUCACUGUUAUCCGAUAGCAGCGCGGGAUGAGGGUCAAUGCGUCAUA3' | 88 | 51.14% | Kd: 8.56 nM | 2005 |
| HA influenza virus_Kumar_1 | Hemagglutinin influenza virus (HA influenza virus) | 5'GGGAGAAUUCCGACCAGAAGGGUUAGCAGUCGGCAUGCGGUACAGACAGACCUUUCCUCUCUCCUUCCUCUUCU3' | 74 | 54.05% | Kd: 188 ± 36 pM | 2005 |
| HA influenza virus_Kumar_2 | Hemagglutinin influenza virus (HA influenza virus) | 5'GGGAGAAUUCCGACCAGAAGGGUUAGCGGUCGUCUUAAGUAGUUUUUGGUCCUUUCCUCUCUCCUUCCUCUUCU3' | 74 | 48.65% | Kd: 115 ± 23 pM | 2005 |
| 3Dpol_Stonehouse_1 | RNA-dependent RNA polymerase (3Dpol) | 5'GGGAAGGGAUCCACAUCUACAAAUUCCUUCAUAAUAAACCCGUCCACGCCCUUCGAAGCAGUUCAGACGUCACUU3' | 75 | 48.00% | Kd: 460 nM | 2006 |
| 3Dpol_Stonehouse_2 | RNA-dependent RNA polymerase (3Dpol) | 5'GGGAAGGGAUCCAAUCUACAAAUUCGUUAACAGAAAACCUCAGUUGCUGGGUUGUUUUCACUGCAAACUUGACAAAGCUA3' | 80 | 41.25% | Kd: 375 ± 46 nM | 2006 |
| 3Dpol_Stonehouse_3 | RNA-dependent RNA polymerase (3Dpol) | 5'GGGAAUGGAUCCACAUCUACGAAUUCCUUACCCGUGAACCGCAGUUGCUGAGUUGUUCGAAGCAGUUCAGACGUCACUU3' | 79 | 49.37% | Kd: 625 nM | 2006 |
| 3Dpol_Stonehouse_4 | RNA-dependent RNA polymerase (3Dpol) | 5'GGGUUAACAGAAAACCUCAGUUGCUGGGUUGU3' | 32 | 46.88% | Kd: 325 | 2006 |
| polβ_Miller_1 | DNA polymerase beta (polβ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGGUUGGGUUGUCGUAGAUAGAGCGCUUCAAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 47.50% | Kd: 290 ± 80 nM | 2006 |
| polκ_Miller_2 | DNA polymerase kappa (polκ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGGUUGGGUUGUCGUAGAUAGAGCGCUUCAAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 47.50% | Kd: 410 ± 50 nM | 2006 |
| polβ_Miller_3 | DNA polymerase beta (polβ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGGUUGGGUUGUCGUAGAUAUAGCUUAGCCAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 46.25% | Kd: 430 ± 130 nM | 2006 |
| polκ_Miller_4 | DNA polymerase kappa (polκ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGGUUGGGUUGUCGUAGAUAUAGCUUAGCCAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 46.25% | Kd: 500 ± 100 nM | 2006 |
| polβ_Miller_5 | DNA polymerase beta (polβ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGGGUGGGUUGUCGUGGAUGACGAUUAUCAGUUCACUGCAGACUUGACGAAGCUU3' | 80 | 48.75% | NA | 2006 |
| polβ_Miller_6 | DNA polymerase beta (polβ) | 5'GGGAAUGGAUCCACAUCUACGAAUUUCGGGGGGGUUGUUCGUGGAAAAUGCUUGCGUUCACUGCAGACUUGACGAAGCUU3' | 80 | 50.00% | Kd: 490 ± 70 nM | 2006 |
| polκ_Miller_7 | DNA polymerase kappa (polκ) | 5'GGGAAUGGAUCCACAUCUACGAAUUUCGGGGGGGUUGUUCGUGGAAAAUGCUUGCGUUCACUGCAGACUUGACGAAGCUU3' | 80 | 50.00% | Kd: 750 ± 160 nM | 2006 |
| polβ_Miller_8 | DNA polymerase beta (polβ) | 5'GGGAAUGGAUCCACAUCUACGAAUUCGUUAACUGACCCAGGGAAGUGCCACCCCCCUUCACUGCAGACUUGACGAAGCUU3' | 80 | 52.50% | NA | 2006 |
| ovine Prion protein_Marc_1 | RecombiNAt ovine PrP (Prion protein) of the susceptible-specific (V136R154Q171) or resistant-specific (A136R154R171) alleles | 5'GAGGAUCCGCCGAGUAACAGACGUCGGGGAUUGGCAAACCCCGUUUCCUUGAGCGACCCCCUUGAGGCUCGAAUUCGCCC3' | 80 | 61.25% | Kd: 28.9 ± 0.8 nM (VRQ), Kd: 14.6 ± 1.3 nM (ARR) | 2006 |
| ovine Prion protein_Marc_2 | RecombiNAt ovine PrP (Prion protein) of the susceptible-specific (V136R154Q171) or resistant-specific (A136R154R171) alleles | 5'GAGGAUCCGCCGAGUAACAGACGUCGGGGAUUGGCAAACCCCGUUUCCUUGAG3' | 53 | 58.49% | NA | 2006 |
| ovine Prion protein_Marc_3 | RecombiNAt ovine PrP (Prion protein) of the susceptible-specific (V136R154Q171) or resistant-specific (A136R154R171) alleles | 5'GGCAAACCCCGUUUCCUUGAGCGACCCCCUUGAGGCUCGAAUUCGCCC3' | 48 | 62.50% | NA | 2006 |
| ovine Prion protein_Marc_4 | RecombiNAt ovine PrP (Prion protein) of the susceptible-specific (V136R154Q171) or resistant-specific (A136R154R171) alleles | 5'GAGGAUCCGCCGAGUAACAGAGUAGCAACAGAAUUGGAUCCCGACCACUAAGAACCCGGCCUUGAGGCUCGAAUUCGCCC3' | 80 | 56.25% | Kd: 72.6 ± 3.7 nM (VRQ), Kd: 23.2 ± 0.5 nM (ARR) | 2006 |
| ovine Prion protein_Marc_5 | RecombiNAt ovine PrP (Prion protein) of the susceptible-specific (V136R154Q171) | 5'GAGGAUCCGCCGAGUAACAGUGCCAUGAGUGAAAUAAAACCAUCCGGAACUAAGACUGCGCUUGAGGCUCGAAUUCGCCC3' | 80 | 52.50% | Kd: 55.3 ± 1.4 nM (VRQ) | 2006 |
| ovine Prion protein_Marc_6 | RecombiNAt ovine PrP (prion protein) of the susceptible-specific (V136R154Q171) or resistant-specific (A136R154R171) alleles | 5'GAGGAUCCGCCGAGUAACAGCGUGCAGGUACUAGCUCCACCCCGAGGGGGCACAUCAUUUCUUGAGGCUCGAAUUCGCCC3' | 80 | 60.00% | Kd: 20 nM | 2006 |
| CED-9_Xue_1 | Caenorhabditis elegans Bcl-2 homolog CED-9 | 5'AGGGAGGACGAUGCGGGGUGCUUCGAGCGUAGGAAGAAAGCCGGGGGCUGCAGAUAAUGUAUAGCCAGACGACGGA3' | 76 | 59.21% | Kd: ~4nM | 2006 |
| CED-9_Xue_2 | Caenorhabditis elegans Bcl-2 homolog CED-9 | 5'AGGGAGGACGAUGCGGGAUGGACGCUUAUCCGCAUAGAGGUUUACUACUUCGGAGACUGCCGAUACAGACGACGGA3' | 76 | 55.26% | Kd: ~16 nM | 2006 |
| Bovine factor IX_Mizuno_1 | Bovine factor IX | 5'GGGAGCUCAGCCUUCACUGC-CUACGCGGGCGUUUACGUAACGGCUUAUGGGGAGCUGAGCGCUUGACCGUGGUAGUGCUAAGCAGUAAACGAG-GGCACCACGGUCGGAUCCAC3' | 113 | 60.18% | Kd: 10 nM | 2006 |
| Hemagglutinin_Kumar_1 | Influenza B virus hemagglutinin (HA) (B/Johannesburg/05/1999), Human | 5'GGGAGCUCAGCCUUCACUGCACUCCGGCUGGUGGACGCGGUACGAGCAAUUUGUACCGGAUGGAUGUUCGGGCAGCGGUGUGGCAGGGAUGAGCGGCACCACGGUCGGAUCCAC3' | 114 | 64.04% | Kd: 44 ± 6 nM | 2006 |
| B1-CT_Famulok_1 | Cytoplasmic tail of BACE (B1-CT) | 5'GGGAUAGGAUCCACAUCUACGUAUUACGCAACGCCGGGCCACUACGCGAAUGGCAAGCCCGUCGACUUCACUGCAGACUUGACGAAGCUU3' | 90 | 55.56% | Kd: 280 nM | 2006 |
| B1-CT_Famulok_2 | Cytoplasmic tail of BACE (B1-CT) | 5'GGGAUAGGAUCCACAUCUACGUAUUAGUACACGUCGGCCACCUACGCGAAGUGGAAGCCUCAUUUGUUCACUGCAGACUUGACGAAGCUU3' | 90 | 50.00% | Kd: 360 nM | 2006 |
| Haemagglutinin_Kumar_1 | Haemagglutinin (HA) region of the target strain A/Panama/2007/1999(H3N2) | 5'GGGAGAAUUCCGACCAGAAGGGUUAAGCAGUCGGCAUGCGGUACAGACAGACCUUUCCUCUCUCCUUCCUCUUCU3' | 75 | 53.33% | Kd: 188 pM | 2006 |
| rTGF_Nakamura_1 | RecombiNAt transforming growth factor-beta type III receptor displayed on cell surface | 5'GGGCCAGGCAGCGAGAGAUAAGCAGAAGAAGUAUGUGACCAUGCUCCAGAGAGCAACUUCACAUGCGUAGCCAAACCGACCACACGCGUCCGAGA3' | 95 | 55.79% | Kd: 2.47 nM | 2006 |
| Coedine_Smolke_1 | Coedine | 5'GGGACAGGGCUAGCAGUAGGAUUGGGUGAGGGGAUGUGCUGUGGAGGCAAAGCUUCCG3' | 58 | 60.34% | Kd: 4.00 ± 0.13 μM | 2006 |
| Coedine_Smolke_2 | Coedine | 5'GGGACAGGGCUAGCUUAGUGCUAUGUGAGAAAAGGGUGUGGGGGGAGGCAAAGCUUCCG3' | 59 | 57.63% | Kd: 2.50 ± 0.06 μM | 2006 |
| S37A-β-catenin_Jeong_1 | S37A-β-catenin, Human | 5'GGACGCGUGGUACCAGGCCGAUCUAUGGACGCUAUAGGCACACCGGAUACUUUAACGAUUGGCUAAGCUUCCGCGGGGAUC3' | 81 | 56.79% | Kd: ~5.0 nM | 2006 |
| AMPA receptor_Jayaraman_1 | Alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) (α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors | 5'ACCGAGUCCAGAAGCUUGUAGUACUCGGCGAACUACCUAACCCCCCACAAUUGUAUUAUCGCCCGCCUAGAUGGCAGUUGAAUUCUCCCUAUAGUGAGUCGUAUUAC3' | 107 | 48.60% | Kd: 37 ± 5 nM | 2007 |
| Thyroxine_Perreault_1 | Thyroxine (T4) | 5'GAAUUCGUCGACGGAUCCGCAGUGCGUCUUGGGUUGUGAGCUCCCGGCUCGCAUUGUGAGGUGGAGGGGGACGUGCUGCAGGUCGACGCAUGCGCCG3' | 97 | 64.95% | Kd: 50±10 μM | 2007 |
| Calsenilin_Yu_1 | Biased conformation(s) of calsenilin | 5'GGGACGCGUGGUACCGACGGAGGCUUGUUUAUGUAGGGAUGUAAGGGGAUGGGCAAUGUGGCGACAGCUUCCGCGGGGAUC3' | 81 | 60.49% | Kd: 43 nM for Ca2+ bound, 79 nM for Ca2+ unbound | 2007 |
| Calsenilin_Yu_2 | Biased conformation(s) of calsenilin | 5'GGGACGCGUGGUACCAAAGAGGCUGCGCGGAAGUGAGGGUGUUGGUUACGAAGGUUGGUGUGUGAAGCUUCCGCGGGGAUC3' | 81 | 60.49% | Kd: 190 nM for Ca2+ bound | 2007 |
| RF-1_Aoyama_1 | Release factor 1, Escherichia coli (E. Coli) | 5'GGACCGAGAAGYYACCCAGGAUUGCGUGUUAAGGCGCUCGGCUCGAUAUUUAUGCUGGUCAUGGUGGACGCACAUCGCAGCAAC3' | 82 | 56.10% | Kd: 30 ± 6 nM | 2007 |
| beta(2)m fibrils_Stockley_1 | Amyloid-like fibrils formed in vitro from monomeric beta-2-microglobulin (β2m) | 5'GGGCCAAGCUUGCAUGCCUGCAGUUGGUUACGCGUACAGUGAAACUCGGAAAGUUGAAGGGCCAAAUGGGAACGGUACCGAGCUCAGGUUCCC3' | 93 | 55.91% | Kd: 1.15E-08 M | 2007 |
| beta(2)m fibrils_Stockley_2 | Amyloid-like fibrils formed in vitro from monomeric beta-2-microglobulin (β2m) | 5'GGGCCAAGCUUGCAUGCCUGCAGAAAAAUAAAGUGUGUACACUAAAUUGCUAGCCCCCGGAAAGAAGGUCAACAAAAGUCAGUGGUACCGAGCUCAGGUUCCC3' | 103 | 49.51% | Kd: 7.48E-09 M | 2007 |
| beta(2)m fibrils_Stockley_3 | Amyloid-like fibrils formed in vitro from monomeric beta-2-microglobulin (β2m) | 5'GGGCCAAGCUUGCAUGCCUGCAGGCAAACGGGGGCGUUUCGGCGGAGGAGUGGGAAGAAAAACGAGAGAAGAGUUGGAACGGGUACCGAGCUCAGGUUCCC3' | 101 | 60.40% | Kd: 2.21E-08 M | 2007 |
| GluR2 glutamate receptor_Niu_1 | RecombiNAt GluR2Qflip AMPA receptor transiently expressed in HEK-293 (human embryonic kidney) cells | 5'GGGCGAAUUCAACUGCCAUCUAGGCAGUAACCAGGAGUUAGUAGGACAAGUUUCGUCC3' | 58 | 50.00% | Kd: 0.419 ± 0.221 nM & IC50: 121 ± 7 nM | 2007 |
| GRK2_Blind_1 | G-protein-coupled receptor kinase 2 (GRK2) | 5'CUGCAGUUCGGGUAGCACAGACCAUACGGGAGAGAAACUUGUGCAACCCGGGGCUAC3' | 57 | 57.89% | Kd: 78.2 nM ± 2.6 nM | 2008 |
| GRK2_Blind_2 | G-protein-coupled receptor kinase 2 (GRK2) | 5'GGUUCGGGUAGCACAGACCAUACGGGAGAGAAACUUGUGCAACCCGGGGCU3' | 51 | 58.82% | Kd: 101.2 nM ± 7.2 nM | 2008 |
| Mbl_Berglund_1 | Drosophila muscleblind protein (Mbl) | 5'GGGAAUGGAUCCACAUCUACGAAUUCACCGUAGAUGAUGGAUGUGCGGUAGAGUCUUUCACUGCAGACUUGACGAAGCUU3' | 80 | 47.50% | Kd: 0.23 nM ± 0.09 | 2008 |
| bPrP_Nishikawa_1 | Bovine Prion Protein (bPrP) | 5'GGGAGGUGGAACUGAAGGAGACAAUCCAUUCAUCUCUCGAAUGAGGAAGUAGCCCAAGAGGAGGAGGAGGAUGAGCACUUCGCAAUCGCUCUACGCA3' | 97 | 52.58% | Kd: 82 ± 21 nM | 2008 |
| TfR-ECD_Neufeld_1 | Mouse transferrin receptor (TfR-ECD) | 5'GGGCGAAUUCCGCGUGUGCUGAGGGCGGAAGAACUAAUUUGGGACGGAUUGCGGCCGUUGUCUGUGGCGUCCGUUCGGG3' | 79 | 62.03% | NA | 2008 |
| TfR-ECD_Neufeld_2 | Mouse transferrin receptor (TfR-ECD) | 5'GGACGGAUUGCGGCCGUUGUCUGUGGCGUCCGUUCG3' | 36 | 66.67% | NA | 2008 |
| Abeta_Mihara_1 | Amyloid beta-peptide (Aβ) | 5'GGGAUGUUCUAGGCGGUUGAUGAUAGCGUAUGCCACUCUCCUGGGACCCCCCGCCGGAUGGCCACAUCCAGAGUAGCAUAAUUGAUCCGA3' | 90 | 56.67% | Kd: 21.6 μM | 2009 |
| Abeta_Mihara_2 | Amyloid beta-peptide (Aβ) | 5'GGGAUGUUCUAGGCGGUUGAUGAUUUGGGGUGUCGGGCGAUUUUUAGGGUUGGGCCAGGCCGUCAUCCAGAGUAGCAUAAUUGAUCCGA3' | 89 | 52.81% | Kd: 10.9 μM | 2009 |
| PAI-1_Fortenberry_1 | Serine protease inhibitor plasminogen activator inhibitor-1 (PAI-1) | 5'GGGAGGACGAUGCGGAUCAACUCACCGUAGGUCUAGUGAGAACUUCAAGUCUACUCAGACGACUCGCUGAGGAUCC3' | 76 | 53.95% | Kd: 177 pM | 2009 |
| PAI-1_Fortenberry_2 | Serine protease inhibitor plasminogen activator inhibitor-1 (PAI-1) | 5'GGGAGGACGAUGCGGAGCGACUGACGAUCUUGAGUAAACCGCUCAUCCACGUAGUCAGACGACUCGCUGAGGAUCC3' | 76 | 57.89% | Kd: 920 pM | 2009 |
| SARS-CoV N protein_Oh_1 | SARS-CoV nucleocapsid (N) protein | 5'GGGAGAGCGGAAGCGUGCUGGGCCUGUCGUUCGCUGUCUUGCUACGUUACGUUACACGGUUGGCAUAACCCAGAGGUCGAUGG3' | 83 | 59.04% | Kd: 1.65 ± 0.41 nM | 2009 |
| EGFR_Ellington_1 | Epithelial Growth Factor Receptor (EGFR) | 5'GGCGCUCCGACCUUAGUCUCUGCAAGAUAAACCGUGCUAUUGACCACCCUCAACACACUUAUUUAAUGUAUUGAACGGACCUACGAACCGUGUAGCACAGCAGA3' | 104 | 48.08% | kd: 7 nM | 2009 |
| ASR_Rao_1 | Sulforhodamine analogue (ASR) fluorogen | 5'GAAGCUUGGGAAUUCGAGCUCCUGACAGCAGGACCCUCACCUCGGUGAUGAUGGAGGGGCGCAAGGUUAACCGCCUCAGGGUCCUCGAUUCGAAGACGUCCAGCUGAUCUAGAUUCUAUAGUGUCACCUAAAU3' | 133 | 53.38% | Kd: 39.1 ± 7.6 μM or 3.5 ± 1.5 μM | 2010 |
| ASR_Rao_2 | Sulforhodamine analogue (ASR) fluorogen | 5'GGACAGCAGGACCCUCACCUCGGUGAUGAUGGAGGGGCGCAAGGUUAACCGCCUCAGGGUCCUCGACUCGAAGACGUCCAGCUGAUCC3' | 88 | 62.50% | Kd: 26.9 ± 2.2 μM | 2010 |
| PTP1B_Tremblay_1 | Protein tyrosine phosphatase 1B (PTP1B) | 5'GGGAAUGGAUCCACAUCUACUGUGAUCAAUUUGGCAAUCCGCCACACGAGACUGCAGACUUGACGAAGCUU3' | 71 | 49.30% | Ki: 200 pM | 2010 |
| PTP1B_Tremblay_2 | Protein tyrosine phosphatase 1B (PTP1B) | 5'm(GA)AUUCUGUGAUCAAUUUGGCAAUCCGCCACACGAGUm(UsC)3' | 39 | 46.15% | Ki: 166 nM and 168 nM | 2010 |
| PTP1B_Tremblay_3 | Protein tyrosine phosphatase 1B (PTP1B) | 5'GGGAAUGGAUCCACAUCUACUGUGAUUAAUUUGGCAAUCCGCCACACUAGACUGCAGACUUGACGAAGCUU3' | 71 | 46.48% | Ki: 250 nM | 2010 |
| SPC_Waga_1 | Sphingosylphosphorylcholine (SPC) | 5'GGGAAUGGAUCCACAUCUACGAAUUCUACCGUUAUUGGUGUCACCGAAGAUGUUAUUCACUGCAGACUUGACGAAGCUU3' | 79 | 44.30% | Kd: 20.9 ± 0.19 nM | 2010 |
| SPC_Waga_2 | Sphingosylphosphorylcholine (SPC) | 5'GGGAAUGGAUCCACAUCUACGAAUUCUUCCGUUAUUGGAGCCAAGUCGUAUCCCGAUUCACUGCAGACUUGACGAAGCUU3' | 80 | 47.50% | Kd: 33.2 ± 0.19 nM | 2010 |
| SPC_Waga_3 | Sphingosylphosphorylcholine (SPC) | 5'GGAAUGGAUCCACAUCUACGAAUUCGCAUUGUCCGCACGCAAAGCAUUAUUGUGAUUCACUGCAGACUUGACGAAGCUU3' | 79 | 45.57% | Kd: 90.4 ± 2.35 nM | 2010 |
| SPC_Waga_4 | Sphingosylphosphorylcholine (SPC) | 5'GGGAUCCACAUCUACGAAUUCUACCGUUAUUGGUGUCACCGAAGAUGUUAUUCC3' | 54 | 44.44% | Kd: 186 ± 5.05 nM | 2010 |
| SPC_Waga_5 | Sphingosylphosphorylcholine (SPC) | 5'GGAUCUACGAAUUCUACCGUUAUUGGUGUCACCGAAGAUCC3' | 41 | 46.34% | Kd: 252 ± 7.04 nM | 2010 |
| SPC_Waga_6 | Sphingosylphosphorylcholine (SPC) | 5'GGGAUCCACAUCUACGAAUUCUUCCGUUAUUGGAGCCAAGUCGUAUCCCGAUUCC3' | 55 | 49.09% | Kd: 221 ± 4.84 nM | 2010 |
| SPC_Waga_7 | Sphingosylphosphorylcholine (SPC) | 5'GGCGAAUUCUUCCGUUAUUGGAGCCAAGUCGCC3' | 33 | 54.55% | Kd: 196 ± 2.98 nM | 2010 |
| ZAP_Gao_1 | Zinc-finger antiviral protein (ZAP) | 5'GGGAACAGUCCGAGCCUGCGUGCGAGGAGGUGGAGAGGGUGGGUGUGCGUGGCGUGGGGUGAAUUCGUCAUA3' | 72 | 63.89% | NA | 2010 |
| ZAP_Gao_2 | Zinc-finger antiviral protein (ZAP) | 5'GGGAACAGUCCGAGCCAAGCGGUAGCGUCAGGGGGUGGAGGGAGGAGGCCGCGUGGUGUGGGUGAAUUCGUCAUA3' | 75 | 64.00% | NA | 2010 |
| IL-17A_Nakamura_1 | Interleukin-17A (IL‐17A) | 5'UAAUACGACUCACUAUAGGGAGCAGGAGAGAGGUCAGAUGGGUCUAGCCGGAGGAGUCAGUAAUCGGUAGACCCAUCUGACCUCUCUCCUGCUCCC3' | 96 | 54.17% | Kd: 48.5 pM | 2011 |
| E.coli_O157:H7_Lee_1 | Escherichia coli (E. coli) O157:H7 | 5'GGGAUACCAGCUUAUUCAAUUUGAUUCCAUCUUCCUGGACUGUCGAAAAUUCAGUAUCGGGAGGUUACGUAUUUGGUUUAUAGAUAGUAAGUGCAAUCU3' | 99 | 38.38% | Kd: 110 nM | 2011 |
| HPV-16 E7_Salas_1 | Human papillomavirus type 16 (HPV-16) E7 oncoprotein | 5'UAAUACGACUCACUAUAGGGAGACCCAAGCCGAUUUAUUUUGUGCAGCUUUUGUUCCCUUUAGUGAGGGUUAAUU3' | 75 | 40.00% | Kd: 1.9 µM | 2011 |
| HBV P protein_Hu_1 | RecombiNAt truncated human hepatitis B virus (HBV) P protein (miniP) | 5'UGUUCAUGUCCUACUGUUCAAACAAAAAAACUGUGCACAAAAAUAAAUUGGGGCAUGGACA3' | 61 | 36.07% | NA | 2011 |
| HBV P protein_Hu_2 | RecombiNAt truncated human hepatitis B virus (HBV) P protein (miniP) | 5'UGUUCAUGUCCUACUGUUCACAGAAAAUAGCUGUGCAAAAAAAAAAGAUGGGGCAUGGACA3' | 61 | 39.34% | NA | 2011 |
| Ser-Tyr-Gly(in GFP)_Jaffrey_1 | The fluorophore in Green fluorescent protein (GFP) (Ser65-Tyr66-Gly67) | 5'GACGCAACUGAAUGAAAUGGUGAAGGACGGGUCCAGGUGUGGCUGCUUCGGCAGUGCAGCUUGUUGAGUAGAGUGUGAGCUCCGUAACUAGUCGCGUC3' | 98 | 55.10% | KD: 537 nM | 2011 |
| Ser-Tyr-Gly(in GFP)_Jaffrey_2 | The fluorophore in Green fluorescent protein (GFP) (Ser65-Tyr66-Gly67) | 5'UCUAGAAUUCAAUUUGCGUAUUGAGACAGGGCCGCGCUAUUUCUGGAGGGGCGGUACAUGAAAGUGGUGGUUGGGUGCGGUCGGAGAUAGCUCGAGCAAUGC3' | 102 | 52.94% | KD: 464 nM | 2011 |
| Ser-Tyr-Gly(in GFP)_Jaffrey_3 | The fluorophore in Green fluorescent protein (GFP) (Ser65-Tyr66-Gly67) | 5'GGGAGAUACGCUCUAGAAUUCAAUUGCAUGGUGGUCUGGGACAGACGUGUGGACGGCACACAGCGUGAGGCUUUGGUGGGUUAUGGCUGUCAUGCGAGAUAGCUCGAGCAAUGC3' | 114 | 54.39% | KD: 406 nM | 2011 |
| OX40_Nair_1 | OX40, T cell costimulatory receptor | 5'UCGGGCGAGUCGUCUGGGGAGGACGAUGCGGAAAAAAGAACACUUCCGAUUAGGGCCCACCCUAACGGCCGCAGGGGAGGACGAUGCGGCCGCAUCGUCCUCCCUA3' | 106 | 63.21% | Kd: 1.7 nM | 2012 |
| OX40_Nair_2 | OX40, T cell costimulatory receptor | 5'UCGGGCGAGUCGUCUGGGGAGGACGAUGCGGAACGGGACCACCCAUGCCAGGGGACCACCUCAGGCAGCGCCAGACGACGGGAGGACGAUGCGGCCGCAUCGUCCUCCCUA3' | 111 | 69.37% | Kd: 10 nM | 2012 |
| HIRRV-Aoki_1 | Hirame rhabdovirus (HIRRV) | 5'GGUGUAUAGGUAUUGAAUCAAUUGUUUUAGCGUUGUCUUA3' | 40 | 32.50% | NA | 2012 |
| HIRRV-Aoki_2 | Hirame rhabdovirus (HIRRV) | 5'GGAACGCGAGCUUAGAUUUCGGAGAACAGUUUGUAAUUGUU3' | 41 | 41.46% | NA | 2012 |
| HIRRV-Aoki_3 | Hirame rhabdovirus (HIRRV) | 5'GUCCUAUACAGUGUGACCGGUUGAAAGUGGGUUCGUUG3' | 38 | 50.00% | NA | 2012 |
| HIRRV-Aoki_4 | Hirame rhabdovirus (HIRRV) | 5'GGGUUAAGCCGGAUUGUAGACUGUAACAGGUAGAGCUGGC3' | 40 | 52.50% | NA | 2012 |
| CypB_White_1 | Cyclophilin B (CypB) | 5'GGGAGGACGAUGCGGGGACCUAUGCAGUAGCCAGUGUGGACUGGGCUGCCCCCCCCAGACGACUCGCCCGA3' | 71 | 69.01% | Kd: 1.5 ± 0.02 nM | 2012 |
| hMMP-9_Toulmé_1 | human matrix metalloprotease 9 (hMMP-9) | GGUUACCAGCCUUCACUGCCCUGCCCUCACCCGUUAGCCUGAGCGCCCCGCACCACGGUCGGUCACAC | 68 | NA% | 8.1 ± 3.4 nM | 2012 |
| hMMP-9_Toulmé_2 | human matrix metalloprotease 9 (hMMP-10) | GGUUACCAGCCUUCACUGCUCCCGGACGCGUCUGUAUCCGCUACCCGCCGCACCACGGUCGGUCACAC | 68 | NA% | 15.4 ± 2.8 nM | 2012 |
| hMMP-9_Toulmé_3 | human matrix metalloprotease 9 (hMMP-11) | GGUUACCAGCCUUCACUGCCCUGCGCCAACCCGUUAGCCUUGUCGCCCCGCACCACGGUCGGUCACAC | 68 | NA% | 18.3 ± 3.7 nM | 2012 |
| hMMP-9_Toulmé_4 | human matrix metalloprotease 9 (hMMP-12) | UGCCCUGCCCUCACCCGUUAGCCUGAGCGCCCCGCA | 36 | NA% | Kd: 20 nM | 2012 |
| hMMP-9_Toulmé_5 | human matrix metalloprotease 9 (hMMP-13) | UGCCCUGCCCUCACCCGUUAGCCUGAGCGCCCCGCA | 36 | NA% | NA | 2012 |
| HER2 expressing cell_Dassie_1 | MDA-231/LUC and MDA-MB-231 cell lines | GGGAGGACGAUGCGUCCUUGUCGUCUUGCGUCCCCAGACGACUCGCCCGA | 50 | NA% | 200 nM | 2012 |
| CD133_Duan_1 | CD133-positive on cell line HT-29 | 5'CCCUCCUACAUAGGG'3 | 15 | 60.00% | Kd: 83.2 ± 82.9 nM | 2013 |
| CD133_Duan_2 | CD133-positive on cell line Hep3B | 5'CCCUCCUACAUAGGG'3 | 15 | 60.00% | Kd: 33.9 ± 12.5 nM | 2013 |
| CD133_Duan_3 | CD133-positive on cell line HT-29 | 5'CAGAACGUAUACUAUUCUG3' | 19 | 36.84% | Kd: 145.1 ± 75.4 | 2013 |
| CD133_Duan_4 | CD133-positive on cell line Hep3B | 5'CAGAACGUAUACUAUUCUG3' | 19 | 36.84% | Kd: 52.3 ± 15.8 nM | 2013 |
| CD44_Ismail_1 | Cell-surface Glycoprotein CD44 | 5'GGGAUGGAUCCAAGCUUACUGGCAUCUGGAUUUGCGCGUGCCAGAAUAAAGAGUAUAACGUGUGAAUGGGAAGCUUCGAUAGGAAUUCGG3' | 90 | 47.78% | Kd: 81.3 ± 30.6 nM | 2013 |
| ERα_Shi_1 | Estrogen receptor alpha (ERα) | 5'GGGCAGAGGCACCGCGAACAAAACGCAAGACAGAGUGCCGACAAGAGCACUACAAGCUUCUGCCC3 | 65 | 58.46% | Kd:16 nM | 2014 |
| ERα_Shi_2 | Estrogen receptor alpha (ERα) | 5'GGGAGAAUUCAACUGCCAUCUAGGCACACGCGAGAUAGAGCGAGGCCUCCAAAAAUGGCCACGCCAGGAAGCAGUACUACAAGCUUCUGGACUCGGU3' | 97 | 54.64% | Kd: 21 nM | 2014 |
| ERα_Shi_3 | Estrogen receptor alpha (ERα) | 5'GGGAGAAUUCAACUGCCAUCUAGGCGACCCAGGGCCGGGACGCAAAGCAGCCAAAACAGACGGCCCCAGUCAGGGAGUUACUACAAGCUUCUGGACUCGGU3' | 101 | 58.42% | Kd: 30 nM | 2014 |
| HA_Kumar_1 | Hemagglutinin (HA) of highly pathogenic avian influenza (HPAI H5N1) | 5'UCUAAUACGACUCACUAUAGGAGCUCAGCCUUCACUGCCUGUUAGAGUUUCCUAAAAGCGAACUGGCGCCCUCGUCAGCAUCUGGCAGACGAGUGGAGACGGACUAACCACAGGCACCACGGUCGGAUCCUG3' | 132 | 54.55% | NA | 2014 |
| HA_Kumar_2 | Hemagglutinin (HA) of highly pathogenic avian influenza (HPAI H5N1) | 5'UCUAAUACGACUCACUAUAGGAGCUCAGCCUUCACUGCGAGAUUGUUCUGACCGAGUUGCCUAGCAGGGCAACCGCUGGAACUUGAAGUCGGUAAUGCGAGCGGAAAGCCUUGGCACCACGGUCGGAUCCUG3' | 132 | 54.55% | Kd: 170 pM | 2014 |
| HA_Kumar_3 | Hemagglutinin (HA) of highly pathogenic avian influenza (HPAI H5N1) | 5'UCUAAUACGACUCACUAUAGGAGCUCAGCCUUCACUGCGGUGACCGGAGGAAUACGCGGACGGAGAAAGGGUUGGCCUCGUGGAUGGCGGAUACCCGUCCAGGGAUCUUCUAGGCACCACGGUCGGAUCCUG3' | 132 | 58.33% | NA | 2014 |
| GP2_Ohno_1 | Glygoprotein 2 (GP2), Mouse | 5'GGGAGAAUUCCGACCAGAAGCAAGUAGUUGGCGCCUACUAUAGAAAUACGCCUUUCCUCUCUCCUUCCUCUUCU3' | 74 | 48.65% | Kd: 110 ± 2.6 nM | 2014 |
| gHA1_Kim_1 | Glycosylated receptor-binding domain of the HA protein (gHA1) | 5'GGGUUCACUGCAGACUUGACGAAGCUUGCUUGACGGAGAUCAAGGGCGAGUCGCAUACCAAGUUGAUGGGGAAUGGAUCCACAUCUACGAAUUC3' | 94 | 51.06% | NA | 2014 |
| DFHBI_Jaffrey_1 | RNA Mimic of Green Fluorescent Protein (Fluorophores, coupled with fluorescence-activated cell sorting (FACS); Escherichia coli | 5'GAGACGCAACUGAAUGAAAUGGUGAAGGAGACGGUCGGGUCCAGGCACAAAAAUGUUGCCUGUUGAGUAGAGUGUGGGCUCCGUAACUAGUCGCGUCAC3' | 99 | 52.53% | NA | 2014 |
| DFHBI_Jaffrey_2 | RNA Mimic of Green Fluorescent Protein (Fluorophores, coupled with fluorescence-activated cell sorting (FACS); Escherichia coli | 5'GAGACGGUCGGGUCCAGAUAUUCGUAUCUGUCGAGUAGAGUGUGGGCUC3' | 49 | 55.10% | KD: 360 nM | 2014 |
| DFHBI_Jaffrey_3 | RNA Mimic of Green Fluorescent Protein (Fluorophores, coupled with fluorescence-activated cell sorting (FACS); Escherichia coli | 5'GCCCGGAUAGCUCAGUCGGUAGAGCAGCGGAGACGGUCGGGUCCAGAUAUUCGUAUCUGUCGAGUAGAGUGUGGGCUCCGCGGGUCCAGGGUUCAAGUCCCUGUUCGGGCGCCA3' | 114 | 62.28% | NA | 2014 |
| DFHBI_Jaffrey_4 | RNA Mimic of Green Fluorescent Protein (Fluorophores, coupled with fluorescence-activated cell sorting (FACS); Escherichia coli | 5'GCCCGGAUAGCUCAGUCGGUAGAGCAGCGGAGACGGUCGGGUACGCACAGGGCAAACCAUUCGAAAGAGUGGGACGCAAAGCCUCCGGCCUAAACCAGAAGACAUGGUAGGUAGCGGGGUUACCGAUAGUAGAGUGUGGGCUCCGCGGGUCCAGGGUUCAAGUCCCUGUUCGGGCGCCA3' | 179 | 60.89% | NA | 2014 |
| DFHBI_Jaffrey_5 | RNA Mimic of Green Fluorescent Protein (Fluorophores, coupled with fluorescence-activated cell sorting (FACS); Escherichia coli | 5'GCCCGGAUAGCUCAGUCGGUAGAGCAGCGGAGACGGUCGGGUCCAUCUGAGACGGUCGGGUCCAGAUAUUCGUAUCUGUCGAGUAGAGUGUGGGCUCAGAUGUCGAGUAGAGUGUGGGCUCCGCGGGUCCAGGGUUCAAGUCCCUGUUCGGGCGCCA3' | 157 | 61.15% | NA | 2014 |
| HER2 overexpressing cell line_Abnous_1 | RHER2/neu protein via TUBO cell line | 5'ACCGAGUCCAGAAGCUUGUAGUACUGCUGGAGCAUUUAUGGAUGAACCUUGGACGGAAGCCUAGAUGGAGUUGAAUUCUCCCUAUAGUGAGUCGUAUUAC3' | 100 | 46.00% | Kd: 133.9 ± 12.78 nM | 2015 |
| HIV-1 PR_Prasad_1 | HIV-1 aspartyl protease (PR) | 5'GGGUUACCUAGGUGUAGAUGCUCUUCAUUGUAACUUCUCAUAAUUUCCCGAGGCUUUUACUUUCGGGGUCCUAAGUGACGUCUGAACUGCUUCGAA3' | 96 | 44.79% | Kd: 115 ± 22 nM | 2015 |
| HIV-1 PR_Prasad_2 | HIV-1 aspartyl protease (PR) | 5'GGGUUACCUAGGAGGAGAUGCUACAUUACCUAAGUAAGAUUACGGCUUCGAGUUUAGAGACCUCUCCCUGGUAAGUGACGUCUGAACUGCUUCGAA3' | 96 | 46.88% | Kd: 93 ±19 nM | 2015 |
| HIV-1 PR_Prasad_3 | HIV-1 aspartyl protease (PR) | 5'GGGUUACCUAGGAGGAGAUGCUCUUAAGUGUAACUUCUCAUAACAUCCGGAGGCUUUUACUUCCGGGGACCUAAGUGACGUCUGAACUGCUUCGAA3' | 96 | 47.92% | Kd: 17 ± 3 nM | 2015 |
| HIV-1 PR_Prasad_4 | HIV-1 aspartyl protease (PR) | 5'GGGUUACCUAGGAGGAGAUGCUCUUAAGUGUAACUUCUCGUAAUUCCCAAGGCUUUUACCUCGGGGUCCUAAGUGACGUCUGAACUGCUUCGAA3' | 94 | 47.87% | Kd: 2.2 ± 0.2 nM | 2015 |
| HIV-1 PR_Prasad_5 | HIV-1 aspartyl protease (PR) | 5'GGGUUACCUAGGAGGAGAUGCUUUGACCUAAGGUAAGAUAACGGCUUCGAGUUCAGAGACCUCGCCCUGGUAAGUGACGUCUGAACUGCUUCGAA3' | 95 | 50.53% | Kd: 4.3 ± 0.2 nM | 2015 |
| CA72-4_Lau_1 | Gastrointestinal cancer antigen 72–4 | 5'GGGUCGUGUCGGAUCCUGCGAAGGGGGGCAGAGGUUUGACGCGAGAAAGCUUCUAAGGUAACGAU3' | 65 | 56.92% | Kd: 52.7nM | 2015 |
| REase_Maher_1 | KpnI isoschizomer Acc65I | 5'GGGAUAUCCUUCAUGAUUCGGAAAAGCGUAACCGCGGCCAAUCAUGCAUGAAGCGUUCCAUAUUUUU3' | 67 | 44.78% | Kd: 11.6 ± 2.3 nM | 2015 |
| REase_Maher_2 | KpnI isoschizomer Acc65I | 5'GGGAUAUCCUUCAUGGUGUGAUUAAACGUAAUCUCAAUCGAUCAUGCAUGAAGCGUUCCAUAUUUUU3' | 67 | 37.31% | Kd: 28.7 ± 5.2 nM | 2015 |
| REase_Maher_3 | KpnI isoschizomer Acc65I | 5'GGGAUAUCCCUACAUGAUAAUCGGGUGAGUAAGGCCUAAACAUCAUGCAUGAAGCGUUCCAUAUUUUU3' | 68 | 41.18% | Kd: 419 ± 46.6 nM | 2015 |
| REase_Maher_4 | KpnI isoschizomer Acc65I | 5'GGGAUAUCCUUCAUGAUUCGGAAAAGCGUAACCGCGGCCGAUCAUGCAUGAAGCGUUCCAUAUUUUU3' | 67 | 46.27% | Kd: 18.6 ± 4.5 nM | 2015 |
| IL-6R_Hahn_1 | Soluble pleiotropic cytokine interleukin-6 receptor (sIL-6R) and interleukin-6 receptor domain 3 (IL-6R D3) | 5'AAUGCGAAGAAAGAGGUCUGAGACAUUCUCAACGAACUAUGAGGAAAGGGACCGUGCGAGGGUUGGGUUAGGGUUUGGAGCCACGGUCCUUCUGGAGUUGACGUUGCUU3' | 109 | 51.38% | Kd: 97.7 ± 18.3 nM | 2015 |
| IL-6R_Hahn_2 | Soluble pleiotropic cytokine interleukin-6 receptor (sIL-6R) and interleukin-6 receptor domain 3 (IL-6R D3) | 5'AAUGCGAAGAAAGAGGUCUGAGACAUUCUGAAGAGAGAAAGCCAGUAGAGGGAAGAGGGAUGAGGGACGUGGGAAUCUUGGUAAUCAGUCUUCUGGAGUUGACGUUGCUU3' | 110 | 47.27% | Kd: 179 ± 117 nM | 2015 |
| IL-6R_Hahn_3 | Soluble pleiotropic cytokine interleukin-6 receptor (sIL-6R) and interleukin-6 receptor domain 3 (IL-6R D3) | 5'AAUGCGAAGAAAGAGGUCUGAGACAUUCUUAAAAACGGCCCAUCGUUUGGCRCUGUGGGAGUGGAGGGUGGAUGGUGUUAAGCGAUUCUUCUGGAGUUGACGUUGCUU3' | 107 | 48.60% | Kd: 34.8 ± 5.8 nM | 2015 |
| UCH37_Lee_1 | Proteasome‐associated deubiquitylating enzyme UCH37 | 5'GGGUUCACUGCAGACUUGACGAAGCUUGGAGGGCAUGCUUCGGGCAAACCUGUAGGGGUGCGGCUCUAAUGGAUCCACAUCUACGAAUUC3' | 90 | 54.44% | NA | 2016 |
| IR_Esposito_1 | Glioblastoma cell line U87MG | 5'GGAGACAAGAAUAAACGCUCAAUGAUUUUGCAGCACUUCUUGUUAUCUUAACGAACUGUUGAUGAUUCGACAGGAGGCUCACAACAGGC3' | 89 | 42.70% | Kd: 6 nM | 2016 |
| CCL17_Förster_1 | Chemokine CCL17 | 5'AAUAGAGUCGUCGCGGGUUGGCUCGUAGAUCGGGCCGGUACAGACGACUCGCUGAGGAUCCGAGA3' | 65 | 60.00% | NA | 2018 |
| CCL17_Förster_2 | Chemokine CCL17 | 5'GAGCAGCAUUUGUGGUUUCCCGAUCGCUUCCCCUAAACAGCAGACGACUCGCUGAGGAUCCGAGA3' | 65 | 55.38% | NA | 2018 |
| CCL17_Förster_3 | Chemokine CCL17 | 5'GGGUCGUCGCGGGUUGGCUCGUAGAUCGGGCCGGUACAGACGACCCAGACGACUCGCUGAGGAUCCGAGA3' | 70 | 65.71% | Kd: 0.9 ± 0.1 nM | 2018 |
| CCL17_Förster_4 | Chemokine CCL17 | 5'GAGCAGCAUUUGUGGUUUCCCGAUCGCUUCCC3' | 32 | 56.25% | Kd: 7.5 ± 1.5 nM | 2018 |
| Prostate cancer_Sullenger_1 | Prostate cancer cell line PC-3 | 5'GGGAGGACGAUGCGGGGCUUUCGGGCUUUCGGCAACAUCAGCCCCUCAGCCAUUUCUCCUACUGGGAUAGGUGGAUUAU3' | 79 | 56.96% | Kd: 146-410 nM | 2018 |
| CA50_Lau_1 | Homo sapien - CA50 | 5'GGGUCGUGUCGGAUCCGUGAGUUUUUCGCGGCGAAGACAAGGCUCGAAGCUUCUAAGGUAACGAU3' | 69 | 48.78% | Kd: 38 nM | 2018 |
| CEA_Lau_1 | Homo sapien - CEA | 5'AUCGUUACCUUAGAAGCUUAGGCACGACGCAUAGCCUUGGGAGCGAGGAGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3' | 82 | 51.22% | Kd: 16.5 nM | 2018 |
| CA72-4_Lau_1 | Homo sapien - CA72-4 | 5'GGGUCGUGUCGGAUCCUGCGAAGGGGGGCAGAGGUUUGACGCGAGAAAGCUUCUAAGGUAACGAU3' | 69 | 51.22% | Kd: 52.7 nM | 2018 |
| CEA_Lau_2 | Homo sapien - CEA | 5'AUCGUUACCUUAGAAGCUUAACGGCAUGACCUAACCUGGAGGCGCAUCAGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3' | 82 | 48.78% | Kd: 156.0 nM | 2018 |
| CA72-4_Lau_2 | Homo sapien - CA72-4 | 5'AUCGUUACCUUAGAAGCUUCCCAAAAAGGAUUGGGGCGUCUGCAUGACCGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3' | 82 | 48.78% | Kd: 71.2 nM | 2018 |
| CA50_Lau_2 | Homo sapien - CA50 | 5'AUCGUUACCUUAGAAGCUUAGCUCGAAAGUGGGCUGGCGAUGUGUCCCGGGAUCCGACACGACCCUAUAGUGAGUCGUAUUA3' | 82 | 51.22% | Kd: 30.7 nM | 2018 |
| MLL1_Chun_1 | Mixed lineage leukemia protein 1 (MLL1) | 5'GGCUCGAGGAACGUACAGAGGGUGGAGAGUGGGUGGAAGCUUACGGUACCUAGC3' | 54 | 59.26% | NA | 2019 |
| MLL1_Chun_2 | Mixed lineage leukemia protein 1 (MLL1) | 5'GGCUCGAGGACGUAACAGAGGGAGGCGAGUGGGUGGAAGCUUACGGUACCUAGC3' | 54 | 61.11% | NA | 2019 |
| CD25_Weiner_1 | Soluble Interleukin 2 Receptor α (CD25) | 5'GGGAGGACGAUGCGGUCCUGUCGUCUGUUCGUCCCCAGACGACUCGCCCGA3' | 51 | 66.67% | Kd: 122.0 ± 5.23 nM | 2019 |
| CD25_Weiner_2 | Soluble Interleukin 2 Receptor α (CD25) | 5'GGGAGGACGAUGCGGCGUUUCCUCUGGUUCGUCCCCAGACGACUCGCCCGA3' | 51 | 66.67% | Kd: 96.9 ± 5.77 nM | 2019 |
| CD25_Weiner_3 | Soluble Interleukin 2 Receptor α (CD25) | 5'GGGAGGACGAUGCGGUGAGUCGUUCCCUUCGUCCCCAGACGACUCGCCCGA3' | 51 | 66.67% | Kd: 68.2 ± 2.73 nM | 2019 |
| CD25_Weiner_4 | Soluble Interleukin 2 Receptor α (CD25) | 5'GGGAGGACGAUGCGGGCCGUUGUUGUGUGCCGCCCCAGACGACUCGCCCGA3' | 51 | 70.59% | Kd: 35.7 ± 1.56 nM | 2019 |
| CD25_Weiner_5 | Soluble Interleukin 2 Receptor α (CD25) | 5'GGGAGGACGAUGCGGAUUCUGGUUACUGGCCGCCCCAGACGACUCGCCCGA3' | 51 | 66.67% | Kd: 46.1 ± 1.76 nM | 2019 |
| C. albicans_Bachtiar_1 | C. albicans | CGAAAGACCAACGCAGCCAAACUGAAGCCCCAGUCGCCCCG | 41 | 63.41% | NA | 2019 |
| C. albicans_Bachtiar_2 | C. albicans | AGCCCUCAACCCAGACACCCCCAACCUUCCUCGCCCCCCC | 40 | 70.00% | NA | 2019 |
| MDA-MB-231_Cerchia_1 | Triple-negative breast cancer (TNBC) cell line MDA-MB-231 | 5'UAGGGAAGAGAAGGACAUAUGAUAAGGCCGACGUAAUGUGUCGGUCGUUACGCGUCGUGCACGUUGACUAGUACAUGACCACUUGA3' | 86 | 48.84% | Kd: 59.12 ± 12.93 or 73.02 ± 12 | 2020 |
| MDA-MB-231_Cerchia_2 | Triple-negative breast cancer (TNBC) cell line MDA-MB-232 | 5'UAGGGAAGAGAAGGACAUAUGAUCCGAUCUCACGCGCACCUUCUCUUCAGCGCGCGACUGGCAUUGACUAGUACAUGACCACUUGA3' | 86 | 51.16% | Kd: 21.91 ± 3.08 or 28.93 ± 9.72 | 2020 |
| MDA-MB-231_Cerchia_3 | Triple-negative breast cancer (TNBC) cell line MDA-MB-233 | 5'UAGGGAAGAGAAGGACAUAUGAUCGAUGCGCACCGAUCUCUCUUCUGCACGUCCUUCGGCACAUUGACUAGUACAUGACCACUUGA3' | 86 | 48.84% | Kd: 24.30 ± 4.99 or 23.92 ± 3.59 | 2020 |
| MDA-MB-231_Cerchia_4 | Triple-negative breast cancer (TNBC) cell line MDA-MB-234 | 5'UAGGGAAGAGAAGGACAUAUGAUCCUGCCCCAACCAUCGCUUCCUCGACGCGCGUUGUCGGCAUUGACUAGUACAUGACCACUUGA3' | 86 | 52.33% | Kd: 9.84 ± 1.63 or 10.77 ± 2.41 | 2020 |
| MDA-MB-231_Cerchia_5 | Triple-negative breast cancer (TNBC) cell line MDA-MB-235 | 5'UAGGGAAGAGAAGGACAUAUGAUGCAACGUUGUGGUCCCGUUUGCACUUUGUUUACGCGCGCAUUGACUAGUACAUGACCACUUGA3' | 86 | 46.51% | Kd: 17.17 ± 2.87 or 26.09 ± 3.20 | 2020 |
| MDA-MB-231_Cerchia_6 | Triple-negative breast cancer (TNBC) cell line MDA-MB-236 | 5'UAGGGAAGAGAAGGACAUAUGAUCCUCAGCGCGCAACUUCCCUCCGUUCCCUGCCACGCGUCA3' | 63 | 57.14% | Kd: 26.88 ± 3.68 or 37.36 ± 3.50 | 2020 |
| DUX4_Kinter_1 | Double homeobox protein 4 (DUX4) | 5'AUCCAGAGUGACGCAGCUAACUUAAUCAACCGCAGGUUGAUUAGCCCAUUAGCUGGACACGGUGGCUUAGU3' | 71 | 49.30% | Kd: 20 nM | 2020 |
| Oligomers of Aβ42_Irie_1 | Toxic beta-amyloid 42 dimer (Aβ42) | 5'GGGACGAAGACCAACUGAACUUUGUGGUGGCGGCUACUCGUGUUCUUUUGACUUUGUCCGUGCUGCCACCUUACUUC3' | 77 | 51.95% | Kd: 20 ± 6.0 nM | 2020 |
| SARS-CoV-2_Kjems_1 | SARS-CoV-2 spike protein | 5'GGGGCCACCAACGACAUUUGUAAUUCCUGGACCGAUACUUCCGUCAGGACAGAGGUUGAUAUAAAUAGUGCCCAUGGAUCC3' | 81 | 49.38% | KD:~ 18 nM | 2021 |
| CD19_Catuogno_1 | CD19 | UGAGCCCUGUUCGACAGGAGGCUCA | 25 | 60.00% | Kd:49.9 ± 13 nM | 2021 |
| CD19_Catuogno_2 | CD19 | CCUGUUGUUCGACAGGAGGCUCACAACAGG | 30 | 56.67% | NA | 2021 |
| HER3_Kawakami_1 | human epidermal growth factor receptor 3 (HER3) | GGAUUAAGGAGGUGAUAUUUAUG-CAUUUGUAUGCUCAGUUGUUUAUCACUCUUCUU-UGCGGUGGAGGAGGAGGUAGCUA | 81 | 40.74% | Kd:700 nM | 2021 |
| IL-6R_Kawakami_1 | IL-6 receptor (IL-6R) | GGAUUAAGGAGGUGAUAUUUAUGUAGAUGUAGUAUUCCUACGAAGUAUUAUUCUUCUUGCGGUGGAGGAGGAGGUAGCUA | 80 | 40.00% | Kd:200 ± 200 n M | 2021 |
| Exosomes_Condorelli_1 | breast cancer exosomes | UGUGGCAGUUAAGAAUAGAUCUUCGCUGCGAUU | 33 | 42.42% | Kd:∼0.8 nM | 2021 |
| RCAN1_Sun_1 | Regulator of calcineurin 1 (RCAN1) | AUACAACAAAAACAAAAACAAGAAA | 25 | 20.00% | Kd:293 nM | 2021 |
| FGF5_Sakamoto_1 | Fibroblast growth factor 5 (FGF5) | GGGCUAGCUGAUCGUACCUCUCCGUACUGACCUACAGAGCGACAUACUAGUGUAUCCAGAUACUAACAGCUAACACCC | 78 | 50.00% | Kd:0.7 ± 0.2 nM | 2021 |
| FGF5_Sakamoto_2 | Fibroblast growth factor 5 (FGF5) | GGGCUAGCUGAUCGUACCUAGCGUGAAUCCAACACGCUUGACAUGCAAACUGCAUCCAGAUACUAACAGCUAACACCC | 78 | 50.00% | Kd:0.57 ± 0.02 nM | 2021 |
| FGF5_Sakamoto_3 | Fibroblast growth factor 5 (FGF5) | GGGCGACCUCUCCGUACUGACCUACAGAGCGACAUACUAGUGUAUCCAGAUCGCCC | 56 | 57.14% | Kd:0.118 ± 0.003 nM | 2021 |
| FGF5_Sakamoto_4 | Fibroblast growth factor 5 (FGF5) | GGGCGACCUAGCGUGAAUCCAACACGCUUGACAUGCAAACUGCAUCCAGAUCGCCC | 56 | 57.14% | Kd:0.92 ± 0.04 nM | 2021 |
| HIV-1 CA lattice_Lange_1 | HIV-1 Capsid (CA) lattice tubes | 5'GGAAGAAGAGAAUCAUACACAAGAUCGACGUACCUCAGGGUGGUGUAUGACUGAGGUGAAGACUGUGAACCAUGGCAUGCGGGCAUAAGGUAGGUAAGUCCAUA3' | 104 | 48.08% | Kd: 350 ± 50 nM or Kd: 502 ± 57 nM | 2022 |
| APP_Kwok_1 | Amyloid precursor protein (APP) 3'UTR D-rG4 | 5'L-GCGGCAAGAGUGGGGGAGGGGGGUCGACGCC3' | 33 | 72.73% | Kd:24.06 ± 2.90 nM | 2022 |
| APP_Kwok_2 | Amyloid precursor protein (APP) 3'UTR D-rG5 | 5'GCGGCAAGAGUGGGGGAGGGGGGUCGACGCC3' | 33 | 72.73% | Kd:49.23±4.89nM | 2022 |
| APP_Kwok_3 | Amyloid precursor protein (APP) 3'UTR D-rG6 | 5'GCGGCGCCGAAGGGAGUGUGGGGGGGGGUCGACGCCG3' | 39 | 76.92% | KD:11.14±1.43 nM | 2022 |
| APP_Kwok_4 | Amyloid precursor protein (APP) 3'UTR D-rG7 | 5'GUGGCCCGAGGUGGGCGGGAGGGACGUAGCGGCCAC3' | 36 | 77.78% | Kd:67.54±11.27 nM | 2022 |
| IL-23_Kawakami_1 | IL-23 | 5'GGAUUAAGGAGGUGAUAUUUAUGCGUUCGACGAUGUGCAGAAUGGUUGUUUGUGCGGUGGAGGAGGAGGUAGCUA3' | 75 | 48.00% | NA | 2022 |
| Hypoxic cells_Catuogno_1 | hypoxic phenotype in breast cancer (BC) cells | 5'CGCUGUGUGGAUAACAUGUAGCUACACAAUUCGAACCGC3' | 39 | 48.72% | Kd:∼35 nM | 2022 |
| CD22_Thiel_1 | B cell surface protein CD22 | 5'GGGAGGACGAUGCGGGCCAUUCGUCUUUUCGUCCCCAGACGACUCGCCCGA3' | 51 | 64.71% | NA | 2023 |
| CD22_Thiel_2 | B cell surface protein CD22 | 5'GGGAGGACGAUGCGGUGACUCGUCUGUUUCGUCCCCAGACGACUCGCCCGA3' | 51 | 64.71% | NA | 2023 |
| LipL32_Citartan_1 | LipL32 | 5'GGGAGGACGAUGCGGAUCCGAAGAUCGUCCUGGAGGGAAGGGAGGGUAGGCGCAGCAGACGACUCGCUGAGGAUCCGAGA3' | 80 | 63.75% | Kd:54.45 ± 9.836 nM | 2023 |
| LipL32_Citartan_2 | LipL32 | 5'GGGAGGACGAUGCGGUAUGGGACCGCGUAAGAGUGGGAGGGGGCGGCAGGUUCAUCAGACGACUCGCUGAGGAUCCGAGA3' | 80 | 63.75% | NA | 2023 |
| Vibrio cholerae_Arab_1 | V. cholerae | 5'UCCUCGCAUCGGGGGUGAAGUACCGUGCGAAAGUCGACGG3' | 40 | 62.50% | NA | 2023 |
| Vibrio cholerae_Arab_2 | V. cholerae | 5'CGGUUUUAAGUGGCAAGGCGAUUUGCCUGGGUAGAAUCCG3' | 40 | 52.50% | NA | 2023 |
| Vibrio cholerae_Arab_3 | V. cholerae | 5'GCCUUGGGUAGAGGCCGGUGGGUAUCUCCAUGAGAUGCUC3' | 40 | 60.00% | NA | 2023 |
| AML1 RD_Sakamoto_1 | cute myeloid leukaemia 1 (AML1) Runt domain (RD) | 5'GGGACACAAUGGACGGCCCUGCCACGAUAGCGGCGCGGGAAGUAAAGUAUACACCUAACGGCCGACAUGAGAG3' | 73 | 58.90% | Kd:0.044 ± 0.003 n M | 2023 |
| AML1 RD_Sakamoto_2 | cute myeloid leukaemia 1 (AML2) Runt domain (RD) | 5'GGGACACAAUGGACGGCCCAGCCACCUAGAGCGAGCGCGCAAUGGAGACCCAUUGUAACGGCCGACAUGAGAG3' | 73 | 61.64% | Kd:0.011 ± 0.01 n M | 2023 |
| AML1 RD_Sakamoto_3 | cute myeloid leukaemia 1 (AML3) Runt domain (RD) | 5'GGGACACAAUGGACGGCCCUGCCACCUAGAGCGAGCGCGCAAUGGAGACCCAUUGUAACGGCCGACAUGAGAG3' | 73 | 61.64% | Kd:0.056 ± 0.003 n M | 2023 |
| Cardiomyocyte_Phylactou_1 | cardiomyocyte | 5'UGCAGGUGCAUGUGGGAUCACGCGCGGUUAGGUCGCCGCG3' | 40 | 67.50% | NA | 2023 |
| NS1 Protein_Citartan_1 | dengue NS1 | 5'GGAGCUCAGCCUUCACUGCUUUGAUCUCGUGGGGGUGUGUCGCGGGAGACACCAUGGAAUAUAUGGCUGAUUUCAUGUGGGCACCACGGUCGGAUCCAC3' | 99 | 56.57% | Kd:37.57 ± 10.34 nM | 2023 |
| NS1 Protein_Citartan_2 | dengue NS1 | 5'GGAGCUCAGCCUUCACUGCCGUAGUCGUAUCUCCAUUACCCAGAAUGGUGAUGCGCCGUGAAGAGCGGUUUAGGGAAUUGGCACCACGGUCGGAUCCAC3' | 99 | 56.57% | Kd:41.40 ± 9.29 nM | 2023 |
| Progesterone receptor_Citartan_1 | Progesterone Receptor | 5'GGAGCUCAGCCUUCACUGCUACUUGGGAGGGGAGCGAACCUUCCAGUUCGUCUCUCUUGGGAAAGGGUUUGUAGCUAAUCAGGCACCACGGUCGGAUCCAC3' | 101 | 56.44% | NA | 2024 |
| Progesterone receptor_Citartan_2 | Progesterone Receptor | 5'GGAGCUCAGCCUUCACUGCCUGGGGGCGGGUUGGGUUGUAUCAUUUGCCGUUAGCCUGGUACAAAAGGGAGGCACUGGAGGCACCACGGUCGGAUCCAC3' | 99 | 60.61% | NA | 2024 |
| Progesterone receptor_Citartan_3 | Progesterone Receptor | 5'GGAGCUCAGCCUUCACUGCUUGCUUUUGGGGGUGCCGUACGCAUUGCGGCAGGGGGAAGAGGAGGGUAGCGACCAGUCGAAGGCACCACGGUCGGAUCCAC3' | 101 | 63.37% | Kd:380 nM±35 nM | 2024 |
| Levofloxacin_Suess_1 | levofloxacin | 5'GGGCACUCCAAGCUAGAUCUACCGGUUUGGGUAGUGCGAUUCGCACUGAAUGCCGCGUAGGCUUCGCUACUGGCUUCUACUACGUACCCAAAAUGGCUAGCAAAGGAGAAGAACUUUUCACU3' | 122 | 50.82% | Kd:6 μM | 2024 |
| Levofloxacin_Suess_2 | levofloxacin | 5'GGGUUUGGGUAGUGCGAUUCGCACUGAAUGCCGCGUAGGCUUCGCUACUGGCUUCUACUACGUACCCAAACCC3' | 73 | 56.16% | Kd:6 μM | 2024 |
| IL-17RA_Kawakami_1 | human interleukin-17 receptor A (IL-17RA) | 5'GGAUUAAGGAGGUGAUAUUUAUGAUGAUUGUGUUUUAUCUGCAUCAUAAUGAGUGCGGUGGAGGAGGAGGUAGCUA3' | 76 | 40.79% | Kd:5 nM | 2024 |
| VβBCC_Sakamoto_1 | VβBCC complex | 5'gggagacaagaauaaacgcucaaUUGGAUCGAAACCAUGUAGACAUGGCCAUCCAAAGGGAGAuucgacaggaggcucacaacaggc3' | 87 | 21.84% | Kd:4.3 ± 0.1 nM | 2024 |
| VβBCC_Sakamoto_2 | VβBCC complex | 5'gggagacaagaauaaacgcucaaAAGUGGCCUAGUACUCGACUCOAACCUAGUAGUCUAGGGUuucgacaggaggcucacaacaggc3' | 87 | 21.84% | Kd:9.62 ± 0.02 nM | 2024 |
| VβBCC_Sakamoto_3 | VβBCC complex | 5'GGAGCGAAACCAUGUAGACAUGGCCCUCC3' | 29 | 58.62% | Kd:2.7 ± 0.1 nM | 2024 |
| tRip_Frugier_1 | Plasmodium tRip200-402WT | 5'gggagacaagaauaaacgcucaaAUGAACACCUAGUCAAGACCGUUUAuucgacaggaggcucacaacaggc3' | 72 | 13.89% | Kd:66 ± 2.2 nM | 2024 |
| tRip_Frugier_2 | Plasmodium tRip200-402WT | 5'gggagacaagaauaaacgcucaaGGUGAGAUAACCUGUCAGCACCUAGuucgacaggaggcucacaacaggc3' | 72 | 18.06% | Kd:71.7 ± 6.8 nM | 2024 |
| tRip_Frugier_3 | Plasmodium tRip200-402WT | 5'gggagacaagaauaaacgcucaaACCUGACCUACAGGUAACGCUAACAuucgacaggaggcucacaacaggc3' | 72 | 16.67% | Kd:110 ± 11.8 nM | 2024 |
| tRip_Frugier_4 | Plasmodium tRip200-402WT | 5'gggagacaagaauaaacgcucaaGAGAAGUCAGAUCGAAACACCUAGAuucgacaggaggcucacaacaggc3' | 72 | 15.28% | Kd:37.3 ± 9 nM | 2024 |
| MGSO-3 cells_Goes_1 | MGSO-3 cells | 5'GGGUUGUGUAGAUGAGGUAACUGAUGAAAAUGAUACU8uUAUACAGAAAUUAUCACUCCAGUGACGUCUGAACUGCUUCGAA3' | 82 | 37.80% | NA | 2024 |
| MGSO-3 cells_Goes_2 | MGSO-3 cells | 5'GGGUUGUGUAGAUGCGUCAGUAUCAUUUGGAAAUGUUUUCGUCAUGGAGGUUCCGUGACGUCUGAACUGCUUCGAA3' | 76 | 46.05% | NA | 2024 |
Home
Database
Research
About us